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ABSTRACT 
 
Iron-sulfur (Fe-S) clusters are essential cofactors and are found in all branches of life. In 
eukaryotes, Fe-S assembly complex is composed of NFS1, ISD11, ACP, ISCU2, and FXN 
subunits. NFS1 is a cysteine desulfurase that utilizes a PLP cofactor to extract sulfur from its 
cysteine substrate and produce a persulfide species on a cysteine residue of a mobile S-transfer 
loop. Sulfur is then transferred from the mobile S-transfer loop of NFS1 to ISCU2, where it is 
combined with ferrous iron and electrons to generate [2Fe-2S] clusters. ISD11 and ACP are critical 
for the stability of the Fe-S assembly complex and may modulate NFS1 function. Eukaryotic ISC 
pathway is characterized by low activity of SDA and significant rate enhancement by FXN in 
presence of ISCU2. Prokaryotic cysteine desulfurase IscS (59% identity) stable without accessory 
proteins and highly active. Interestingly, both FXN and homolog CyaY activates/inhibits the 
eukaryotic/prokaryotic Fe-S assembly respectively. 
Here, we investigated the role of FXN/CyaY in each step of Fe-S biosynthesis. We found 
that S-transfer loop cysteine participates in cys-aldimine formation, cys-quinonoid decay, 
persulfide formation on itself, and transfer of this sulfane sulfur to scaffold protein. Interestingly, 
in eukaryotes, FXN enhances all these steps but not as fast as IscS. All these data support a model 
in which monomeric cysteine desulfurase architecture (such as in SDAec) promotes non-productive 
conformations of S-transfer loop of cysteine desulfurase resulting in low activity. FXN binding (in 
eukaryotic system) excludes non-productive conformations and directs the trajectory of the NFS1 
mobile S-transfer loop to position the cysteine to function as a general acid, nucleophile, and sulfur 
delivery agent in different steps and accelerates Fe-S cluster biosynthesis. In prokaryotes, because 
of the closed architecture, the other subunit of cysteine desulfurase regulates S-transfer loop 
 iii 
 
trajectory (better than the FXN in eukaryotic system) and therefore have high activity even in 
absence of FXN. Consistent with this, IscSS10Q variant exhibits significantly weaker dimer 
interface, and concentration dependent enhancement of dimer concentration and activity. Also, 
data indicate that reduced FDX2 is probably not the electron source but sensitizer of persulfide on 
scaffold protein towards reduction by reduced glutathione.  
  
 iv 
 
DEDICATION 
 
This dissertation is dedicated to my parents whose constant encouragement and support 
were invaluable during my Ph.D. 
 
 
 
 v 
 
ACKNOWLEDGEMENTS 
 
I would like to acknowledge my advisor Prof. David Barondeau for giving me the 
opportunity to do research in his lab on a really interesting project and giving me the platform to 
develop myself as an independent researcher. I would also I would like to thank my committee 
members, Prof. Tadhg Begley, Prof. Frank Raushel and Prof. Paul Lindahl for their helpful 
suggestions, support and guidance throughout my career at Texas A&M.  
Additionally, I must also acknowledge Prof. Tadhg Begley for allowing me to use of his 
radio-HPLC, CD spectrometer, and stopped flow apparatus. We also thank Dr. Rung-yi Lai and 
Dr. Jamison P Huddleston for their assistance with the radio-HPLC and KinTek software, 
respectively.  
I would like to thank my colleagues from the Barondeau lab, past and present, specially 
Dr. Deepika Das for their helpful discussions, criticism and suggestions, which were invaluable 
for my research.  
Finally, I would like to thank my friends, family for their amazing support. 
  
 vi 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
This work was supervised by a dissertation committee consisting of Professor David 
Barondeau [advisor] and Professor Tadhg Begley, Professor Frank Raushel and Professor Paul 
Lindahl [committee members].  
All the experiments involving iron sulfur cluster formation or transfer (monitored by CD) 
were conducted and analyzed by Dr. Deepika Das.  
All other work conducted for the dissertation was completed by the student independently. 
Graduate study was supported by NIH, NSF and Welch foundation grants. 
 
 vii 
 
TABLE OF CONTENTS 
 Page 
ABSTRACT ............................................................................................................... ii 
DEDICATION ........................................................................................................... iv 
ACKNOWLEDGEMENTS ....................................................................................... v 
CONTRIBUTORS AND FUNDING SOURCES ..................................................... vi 
TABLE OF CONTENTS ........................................................................................... vii 
LIST OF FIGURES ................................................................................................... ix 
LIST OF TABLES ..................................................................................................... xviii 
CHAPTER I INTRODUCTION AND LITERATURE REVIEW ............................ 1 
Iron sulfur cluster ............................................................................................... 1 
Biosynthetic pathways of iron sulfur cluster ..................................................... 3 
NIF pathway .............................................................................................. 3 
ISC pathway ............................................................................................... 4 
SUF pathway .............................................................................................. 6 
Iron sulfur cluster biosynthetic pathway in eukaryotes ..................................... 6 
Friedreich’s Ataxia (FRDA) and Frataxin ................................................. 9 
Frataxin bypass .......................................................................................... 13 
Mechanism of iron sulfur cluster biosynthesis .................................................. 13 
CHAPTER II MECHANISM FOR ACTIVATION AND BYPASS OF FRATAXIN 
IN HUMAN FE-S CLUSTER BIOSYNTHESIS ................................................. 17 
Introduction ........................................................................................................ 17 
Results ................................................................................................................ 19 
Discussion .......................................................................................................... 27 
Materials and methods ....................................................................................... 31 
Figures ................................................................................................................ 39 
CHAPTER III A CYAY INHIBITS IRON SULFUR CLUSTER BIOSYNTHESIS IN 
PROKARYOTES BY INHIBITING SULFUR TRANSFER FROM ISCS TO 
ISCU ...................................................................................................................... 61 
Introduction ........................................................................................................ 61 
Results ................................................................................................................ 63 
Discussion .......................................................................................................... 66 
Material and methods ......................................................................................... 72 
 viii 
 
Figures ................................................................................................................ 77 
CHAPTER IV DIMER TO MONOMER TRANSITION AND NOT ACTIVE SITE 
RESIDUES EXPLAINS LOW ACTIVITY OF NFS1 ......................................... 94 
Introduction ........................................................................................................ 94 
Results ................................................................................................................ 97 
Discussion .......................................................................................................... 98 
Material and methods ......................................................................................... 99 
Figures ................................................................................................................ 103 
CHAPTER VII CONCLUSION AND FUTURE DIRECTION ............................... 118 
REFERENCES .......................................................................................................... 123 
 
  
 ix 
 
LIST OF FIGURES 
                                                                                                                                               Page 
Figure II-1 Steps of iron sulfur cluster biosynthesis in eukaryotes. ...............................  39  
Figure II-2 Visible CD spectra for holo-ISCU2 and holo-GRX5 have distinct features. 
CD spectra were recorded for 25 µM [2Fe-2S]-ISCU2 (red) and 30 µM 
[2Fe-2S]-GRX5 (blue). ................................................................................  40  
Figure II-3 Final CD spectra for complete Fe-S assembly and transfer reactions 
resemble [2Fe-2S]-GRX5. [2Fe-2S] cluster synthesis and transfer 
reactions to GRX5 for the SDAecU (red), SDAecUF (blue), SDAecU
M106I 
(green) and SDAecU
M106IF (black) complexes. Spectra are shown before 
the reaction is initiated (fine lines) and at end points of assay (bold lines; 
see Figure II-4A). .........................................................................................  41  
Figure II-4 FXN and the ISCU2M106I substitution accelerate different steps in Fe-S 
cluster biosynthesis. A) Kinetics of Fe-S cluster synthesis and transfer to 
GRX5 were monitored for different assembly complexes by the change in 
ellipticity at 450 nm. The average change in ellipticity (n = 3; maximum 
error of 1.8 in ellipticity) is plotted and fit with an exponential rise 
equation. The final CD spectra are shown in Figure II-3. B) Fe-S cluster 
assembly reactions on ISCU2 were monitored for assembly complexes by 
the change in ellipticity at 330 nm. The average change in ellipticity (n = 
3; maximum error of 1.8 in ellipticity) is plotted and fit with a linear 
equation. The complete time course of the reactions and final CD spectra 
are shown in Figure II-5. C) Kinetics of cluster transfer from pre-formed 
holo-ISCU2 to apo-GRX5 were monitoring by the change in ellipticity at 
450 nm. Reactions were initiated (time = 0) by the anaerobic injection of 
GRX5 (with or without FXN). The average change in ellipticity (n = 3; 
maximum error of 0.8 in ellipticity) is plotted and fit with a linear equation. 
The CD spectra before addition of GRX5 and the complete time course of 
the reaction are shown in Figure II-6 and II-7. D) Chemically reconstituted 
ISCU2 (or ISCU2M106I) was reacted with GRX5 and the [2Fe-2S] cluster 
transfer was monitored by the increase in ellipticity at 450 nm. Full spectra 
are shown in Figure II-9. Color scheme: SDAecU (red), SDAecUF (blue), 
SDAecU
M106I (black) and SDAecU
M106IF (green) ..........................................  42  
Figure II-5 Full time course and final CD spectra for Fe-S cluster synthesis reactions 
on ISCU2. A) Fe-S assembly intermediate formation on ISCU2 were 
monitored by the change in ellipticity at 330 nm and shown for different 
assembly complexes.  B) The overall similarity in the final CD spectra 
(after 60 min) for the different complexes indicates the formation of 
analogous Fe-S clusters. The complexes are indicated by their color in the 
 x 
 
figure: SDAecU (red), SDAecUF (blue), SDAecU
M106I (black) and 
SDAecU
M106IF (green). .................................................................................  43  
Figure II-6 Fe-S assembly complexes containing native ISCU2 or ISCU2M106I exhibit 
similar kinetic parameters for the cysteine desulfurase reaction. Cysteine 
desulfurase activities for complexes A) without (SDAecU in red and 
SDAecU
M106I in black) and B) with FXN (SDAecUF in blue and 
SDAecU
M106IF in green) at different concentrations of L-cysteine. Lines 
through the data are the fits to the Michaelis-Menten equation. 
Experiments were performed in triplicate. ...................................................  44  
Figure II-7 CD spectra of Fe-S cluster bound species in transfer reaction from ISCU2 
to GRX5. Fe-S clusters were synthesized in situ on ISCU2 (or ISCU2M106I) 
for A) SDAecU (red), B) SDAecUF (blue) and C) SDAecU
M106I (black) 
complexes. CD spectra are recorded (dotted lines) after 160 min from 
initiation of the reaction. The samples were then spiked with 40 µM GRX5 
(with or without 20 µM FXN) and the CD spectra was recorded 20 min 
later (solid line) later. Kinetic traces monitored at 450 nm are shown in 
Figure II-8. ...................................................................................................  45  
Figure II-8 Incorporation of the ISCU2M106I substitution increases the cluster transfer 
rate from ISCU2 to GRX5. Fe-S clusters were synthesized on ISCU2 in 
reactions described in Figure II-7. The ellipticity at 450 nm was monitored 
for the SDAecU (red), SDAecUF (blue) and SDAecU
M106I (black) 
complexes. Samples were spiked with GRX5 (with or without FXN) 160 
min after the reaction was initiated. Experiments were performed in 
triplicate. ......................................................................................................  46  
Figure II-9 Cluster transfer from chemically reconstituted ISCU2 and ISCU2M106I to 
GRX5. 30 µM [2Fe-2S] cluster bound ISCU2 (black) or ISCU2M106I (grey) 
before (dashed line) and after (solid line) reaction with 60 µM GRX5 in 
the presence of 10 mM GSH ........................................................................  47 
Figure II-10 [2Fe-2S] clusters bound to ISCU2 and ISCU2M106I have comparable 
stabilities. A) [2Fe-2S] clusters were enzymatically assembled on ISCU2 
(red) or ISCU2M106I (blue).  The addition of DTT initiated the cluster 
extrusion reaction, which was followed by the loss of ellipticity at 330 nm. 
The extrusion rates (0.22 mdeg/min for ISCU2 and 0.19 mdeg/min for 
ISCU2M106I) were determined by fits to a linear equation. Experiments 
were performed in duplicate. B) Complete CD spectra are shown for the 
ISCU2 (red) and ISCU2M106I (blue) before (solid line) and 30 min after 
(dashed line) the addition of DTT ................................................................  48 
Figure II-11 Separation of subunits for the SDAecU complex. Assembly complex 
subunits were separated on a reverse phase column (gradient composed of 
CH3CN, isopropanol and TFA; see Methods). ISCU2 (140 µM, red) eluted 
 xi 
 
with a retention time of ~6 min. The SDAec sample (45 µM, blue) had two 
peaks with retention times of ~6 min and ~12 min. The SDAecU sample 
(45 µM SDAec plus 140 µM ISCU2, green) had increased peak intensity 
with a retention time at ~6 min, consistent with the presence of ISCU2 .....  49 
Figure II-12 Separation and detection of [35S]-labeled NFS1. The SDAec complex was 
reacted with L-[35S]-cysteine, quenched with acid, and the proteins were 
separated on a reverse phase column under quench conditions. The 
retention time for NFS1 (~11 min) was identified by the radioactivity peak 
(bottom panel). The band at ~6 min in the top panel was assigned to ISD11 
and/or ACPec. ...............................................................................................  50  
Figure II-13 Evidence that acid quenching inhibits interprotein sulfur transfer. NFS1 
was labeled by combining the SDAec complex with L-[
35S]-cysteine for 30 
min. A) The labeled NFS1 was incubated with ISCU2 for 30 min, followed 
by the addition of the quenching solution. The [35S] label was associated 
with both the NFS1 (peak at ~12 min) and ISCU2 (peak at ~7 min). B) The 
labeled NFS1 was first combined with quenching solution and then 
incubated with ISCU2 for 30 min. The [35S] label was associated with 
NFS1 (peak at ~12 min) but not ISCU2 (peak at ~7 min). Samples were 
analyzed by a reverse phase chromatography similar to Figure II-11 and 
II-12. Note that the peaks for ISD11/ACPec coincides with ISCU2 but have 
no cysteine residues that could form a persulfide species ...........................  51 
Figure II-14 Reactions with excess cysteine result in multiple persulfide species on 
NFS1 and ISCU2. The SDAecU complex (30 µM SDAec and 30 µM 
ISCU2) was reacted with 200 or 600 µM L-[35S]-cysteine at 37 °C and 
quenched at various times. The protein subunits were separated by reverse 
phase chromatography and the amount of radioactivity was quantitated for 
A) NFS1 and B) ISCU2 ...............................................................................  52 
Figure II-15 FXN accelerates the persulfide formation kinetics on both NFS1 and 
ISCU2. SDAecU and SDAecUF complexes were reacted with a 
stoichiometric amount of L-[35S]-cysteine, quenched with acid, and the 
proteins were separated using conditions similar to Figure II-11. Formation 
of [35S]-persulfide was quantitated and plotted for A) NFS1 (SDAecU), B) 
NFS1 (SDAecUF), C) ISCU2 (SDAecU), and D) ISCU2 (SDAecUF). E) 
Best-fit kinetic model (k1 = k3) for persulfide accumulation on cysteine 
residues of NFS1 and ISCU2. The data for SDAecU or SDAecUF were fit 
simultaneously with KinTek and the fits were validated using FitSpace 
(Figure II-16). Blue, green, and red dashed lines represent the simulated 
amounts of persulfide on NFS1, ISCU2, or both NFS1 and ISCU2, 
respectively. Black lines indicate the total amount of simulated persulfide 
on NFS1 or ISCU2 .......................................................................................  53 
 xii 
 
Figure II-16 Analysis of goodness of fit for persulfide formation model by FitSpace.  
Calculation of the (χ2min/ χ2) when k1, k2 and k-2 were varied individually 
for the A) SDAecU and B) SDAecUF complexes. For the best fit parameter 
value, (χ2min/ χ2) approaches one. Deviation from the best fit parameter 
value increase χ2 for the fit and, in turn, decreases the (χ2min/ χ2) value. 
Heatmap describing 2D confidence contour (see Materials and Methods) 
for the C) SDAecU and D) SDAecUF complexes indicate that all the 
parameters are well constrained ...................................................................  54 
Figure II-17 FXN accelerates the persulfide decay kinetics from NFS1. SDAecU (red) 
and SDAecUF (blue) complexes were reacted with stoichiometric amounts 
(30 µM) L-[35S]-cysteine for 40 min and then chased with 1 mM non-
radioactive L-cysteine. Samples were then quenched with acid at various 
times and the amount of remaining [35S]-label on A) NFS1 and B) ISCU2 
were determined. The data were fit to an exponential decay or linear (loss 
of ISCU2 label from SDAecUF complex) equation. C) Model for the effect 
of FXN on persulfide decay from the SDAecU and SDAecUF complexes. 
The NFS1 persulfide is proposed to be the primary species cleaved during 
the chase experiment. In the presence of FXN, the persulfide on NFS1 is 
rapidly regenerated by turnover with non-radioactive L-cysteine. In the 
absence of FXN, slower cysteine desulfurase turnover results in re-
equilibration (transfer) of the ISCU2 radiolabeled sulfur (atom colored red) 
to NFS1 and subsequent cleavage................................................................  55 
Figure II-18 FXN accelerates the decay of the quinonoid intermediate. A) Scheme 
showing steps of PLP chemistry that leads to C-S bond cleavage and 
persulfide formation on the mobile loop cysteine (NFS1-SSH). Stopped-
flow kinetics for the cis-quinonoid decay of B) SDAecU and SDAecUF 
complexes, C) SDAecU and SDAecUCec (includes E. coli FXN homolog 
CyaY), D) SDAecU and SDAecU
M106I and E) SDAecUF and S
C381ADAecUF. 
The traces are an average of three independent experiments. The rates for 
the development and decay of the quinonoid intermediate were obtained 
by nonlinear regression analysis (solid lines) ..............................................  56 
Figure II-19 Effect of FXN on the cys-aldimine and cys-ketimine formation and decay 
kinetics. The SDAecU (red) and SDAecUF (blue) complexes were reacted 
with 10 mM L-cysteine and the absorbance at A) 410 nm (assigned to the 
cys-aldimine intermediate) and B) 340 nm (assigned to the cys-ketimine 
intermediate) were recorded as a function of time in a stopped-flow 
experiment. The lines through the data in A) is a fit to a consecutive B 
equation (see Methods). The data in B) could not be meaningfully fit to a 
rate equation .................................................................................................  57 
Figure II-20 Model for how FXN and the FXN bypass variant accelerate Fe-S cluster 
biosynthesis. A) Cysteine binding to NFS1 generates the Cys-quinonoid 
intermediate. B) In the absence of FXN, the NFS1 mobile S-transfer loop 
 xiii 
 
exists primarily in a non-productive conformation. FXN binding favors the 
active conformation. C) The FXN promoted conformation of the S-transfer 
loop allows its cysteine to function as a general acid and accelerate the 
decay of the cys-quinonoid intermediate. D) The deprotonated cysteine of 
the S-transfer loop nucleophilically attacks the cys-ketimine intermediate 
to generate a persulfide intermediate on NFS1 (NFS1-SSH). E) FXN 
favors the appropriate trajectory to deliver sulfur and produce a persulfide 
species on ISCU2 (ISCU2-SSH). F) A second cysteine turnover generates 
the NFS1-SSH ISCU2-SSH intermediate. G) Incorporation of ferrous iron 
and electrons generates the [2Fe-2S] intermediate on ISCU2. H) The [2Fe-
2S] cluster is transferred to the apo acceptor GRX5. Steps labels in red are 
accelerated by FXN.  Steps labeled in blue are accelerated by the 
ISCU2M106I bypass variant ...........................................................................  58 
Figure III-1 Wavelengths of maximal absorbance (λmax) of PLP intermediates were 
determined by stopped flow. Reaction contained 50 µM IscS and 5 mM 
cysteine (final concentration). These wavelengths were used to determine 
the kinetics of intermediates for all the complexes ......................................  77 
Figure III-2 Both CyaY and IscUI108M does not affect the rate of quinonoid formation 
and decay. The formation and decay of quinonoid intermediate were 
monitored by stopped flow at 508 nm wavelength. Reaction contained 50 
µM all the proteins (IscS, IscU/IscUI108M, CyaY) and 5 mM cysteine (final 
concentrations). The rates were obtained by fitting the data to the equation 
[y=y0 + A*(m1/(m3-m2))(exp(-m2*x)-exp(-m3*x))], where m2 and m3 
values give the apparent rate of formation and decay of the quinoid 
intermediate respectively .............................................................................  78 
Figure III-3 CyaY does not affect the rate of aldimine and ketimine formation and 
decay. The formation and decay of aldimine and ketimine intermediates 
were monitored by stopped flow at 410 and 340 nm wavelength 
respectively. Reaction contained 50 µM all the proteins (IscS, IscU, CyaY) 
and 5 mM cysteine (final concentration). A rate constant for the formation 
and decay of the intermediates could not be determined as the data could 
not be fitted to the equation [y=y0 + A*(m1/(m3-m2))(exp(-m2*x)-exp(-
m3*x))], where m2 and m3 values would have given the apparent rate of 
formation and decay of the intermediate respectively .................................  79 
Figure III-4 CyaY does not affect the rate of persulfide formation on IscS but slows 
down persulfide formation on IscU. (a) Separation of proteins by HPLC. 
50 µM IscS, 150 µM IscU and 50 µM CyaY were loaded onto Deltapack 
C4 column after diluting with quenching solution in 1:3 ratio to a final 
volume of 200 µL (see method). Chromatogram shows that IscS and IscU 
are well separated. Although CyaY co-elutes with IscS, does not affect our 
analysis. (b), (c) Persulfide formation on IscS and IscU in presence and 
absence of CyaY was monitored by reacting 30 uM of IscS, IscU, CyaY 
 xiv 
 
and Cysteine (containing 0.204% 35S-cysteine) at 37ºC for different time 
(in 0 - 20 min range). The samples were analyzed with HPLC and 
scintillation cocktail after quenching with quenching solution (1:4 mixture 
of conc. HCl and 6M guanidine hydrochloride) at given time points. The 
area under IscS and IscU in scintillation trace were converted into amounts 
of persulfide using a standard curve made from 35S-cysteine standard. The 
data were fitted with exponential rise equation [y=m1+m2*(1-exp (-
m3*x))] where m3 value gives the apparent rate of formation which is 
plotted in (d) .................................................................................................  80  
Figure III-5     Both CyaY and IscUI108M does not affect cysteine desulfurase activity. The 
reactions contained 0.5 µM IscS, 2.5 µM IscU/IscUI108M, 5 µM CyaY, 4 
mM D,L-DTT. Reactions were initiated by adding cysteine and incubated 
for 6 min before quenching with DPD and FeCl3 solution. Solutions were 
further incubated for 20 min. Then the samples were centrifuged and 
absorbances at 670 nm were measured, which were converted to 
concentration of sulfide using a standard curve made from known amount 
of sulfide. The data points were fitted to Michaelis-Menten equation (y = 
m1*x/(m2 + x)), where m1 and m2 are kcat and KM respectively .............  81 
Figure III-6     CyaY inhibits cluster assembly on IscU/IscUI108M. Reaction consists of 8 
µM IscS, 40 µM IscU (a) or IscUI108M (b), 50 µM CyaY, 200 µM 
Fe2(NH4)2SO4 and initiated by the addition of 10 mM GSH and 100 µM 
cysteine. The rate is calculated by monitoring the change of ellipticity at 
330 nm and fitting the initial data points to linear equation and plotted in 
(c) .................................................................................................................  82  
Figure III-7     Full reaction showing the effect of CyaY on cluster synthesis on either IscU 
or IscUI108M. Reaction consists of 8 µM IscS, 40 µM IscU (a) or IscUI108M 
(b), 50 µM CyaY, 200 µM Fe2(NH4)2SO4 and initiated by the addition of 
10 mM GSH and 100 µM cysteine. The formation of cluster on 
IscU/IscUI108M is monitored by the change of ellipticity at 330 nm. The fit 
of initial linear portion to a linear equation to determine rate is shown in 
Figure III-6 ...................................................................................................  83 
Figure III-8    CyaY does not affect the rate of cluster transfer from Holo-IscU to apo-
Grx4. (a) Reaction contained 0.5 µM IscS, 20 µM Holo-IscU and 10 mM 
GSH and 40 µM CyaY and was initiated by the addition of 40 µM Grx4. 
The transfer of cluster from Holo-IscU to apo-Grx4 is measured by 
monitoring ellipticity at 450 nm. (b) The rates were obtained by fitting the 
initial data points to linear equation, which is plotted in (c) ........................  84  
Figure III-9    Full spectra of cluster transfer reaction from holo-IscU to apo-Grx4 before 
and after addition of apo-Grx4. Dotted line is before apo-Grx4 addition and 
solid line is after apo-Grx4 addition. Blue traces are for reactions without 
CyaY and red traces are for reactions with CyaY ........................................  85 
 xv 
 
Figure III-10    CyaY inhibits one pot cluster assembly on Grx4 while IscUI108M has no 
effect. Reactions included 0.5 µM IscS, 20 µM IscU (a) or IscUI108M (b), 
40 µM CyaY, 200 µM Fe2(NH4)2SO4 and 40 µM Grx4. The reaction was 
initiated with addition of 100 µM cysteine and 10 mM GSH. Cluster 
assembly on apo-Grx4 was measured by monitoring ellipticity at 450 nm. 
The rates were obtained by fitting the data to linear equation and plotted in 
(c) .................................................................................................................  86  
Figure III-11  Full spectra of one-pot cluster synthesis reaction on Grx4 before and after 
addition of (Cysteine + GSH) mixture, which was used to initiate the 
reaction. Dotted line is before initiation of reaction and solid line is after 
initiation of reaction. Blue traces are for reactions without CyaY and red 
traces are for reactions with CyaY. IscU (wt) was used as scaffold for (a) 
and (b) and IscUI108M was used as scaffold for (c) and (d) ..........................  87  
Figure III-12 Schematic diagram showing the effect of CyaY and IscUI108M on each step. 
CyaY inhibits only sulfur transfer step and IscUI108M has no effect ............  88 
Figure III-13 Correlation between quinonoid accumulation and rate of quinonoid decay. 
Faster quinonoid decay strongly correlates with greater accumulation of 
quinonoid intermediate which is intuitively opposite. As we have shown 
this is due to S-transfer loop cysteine’s participation in aldimine formation 
in the upstream step ........................................................................... 89 
Figure III-14 S-transfer loop cysteine is the proton donor for quinonoid decay. The 
formation and decay of quinonoid, aldimine and ketimine intermediate 
were monitored by stopped flow at 508, 410 and 340 nm wavelength 
respectively. Reaction contained 50 µM of cysteine desulfurase (IscS or 
IscSC328A) and 5 mM cysteine (final concentrations). The rates were 
obtained by fitting the data to consecutive B equation [y=y0 + A*(m1/(m3-
m2))(exp(-m2*x)-exp(-m3*x))], where m2 and m3 values give the 
apparent rate of formation and decay of the intermediates respectively. 
Ketimine kinetics is too complex to fit adequately using consecutive B 
equation. (a) Quinonoid kinetics of wt-IscS. (b) Quinonoid kinetics of 
IscSC328A variant. The decay of quinonoid intermediate is severely 
inhibited. (c) Aldimine kinetics of IscSC328A variant. The maximum amount 
of aldimine formed is much smaller compared to wt-IscS. However, the 
rate of aldimine decay is very similar to wt-IscS. (d) Ketimine kinetics of 
IscSC328A variant. Ketimine formation is very slow and consistent with very 
slow quinonoid decay ..................................................................................  90 
Figure III-15 S-transfer loop cysteine of NFS1 also facilitates cys-aldimine formation 
and accelerates cys-quinonoid decay by proton donation. (a), (b) and (c) 
Cys-aldimine formation takes place in the dead time of the instrument. So, 
we typically don’t see. However, starting amount of cys-aldimine is much 
higher for SDAecUF than that of both SDAecU and S
C381ADAecUF, which 
 xvi 
 
are comparable. This show that s-transfer loop cysteine somehow 
participates in aldimine formation. In contrast, aldimine decay rates are 
comparable for all three complexes. Since aldimine decay is caused by Cα 
proton abstraction, this data shows s-transfer loop cysteine does not 
participate as general base for Cα proton abstraction. (d), (e) and (f) Cys-
ketimine if formed to a greater extent in the case of SDAecUF than that of 
SDAecU and S
C381ADAecUF, which is consistent with previously published 
quinonoid decay kinetics that faster quinonoid decay leads to greater 
accumulation of ketimine intermediate ........................................................  91 
Figure IV-1 Alignment of IscS and NFS1 monomer subunits. Overall the tertiary 
structures are very similar ............................................................................  103 
Figure IV-2 Bridging histidine glutamine pair. Green and cyan denotes different 
subunit ..........................................................................................................  104 
Figure IV-3 Distribution of amino acid residues in the position equivalent to 247, 248 
of IscS among proteobacteria. Beta and Gamma proteobacteria (e.g. E coli) 
has mostly HQ pair in these positions whereas Delta, Epsilon and Alpha 
proteobacteria (which share last common ancestor with mitochondria) has 
other amino acids (Non-HQ) that cannot form hydrogen bonds at the dimer 
interface. Eukaryotes also has non-HQ residues exclusively ......................  105 
Figure IV-4 Distribution of amino acid residues in the position equivalent to 10 of IscS 
among proteobacteria. Beta and Gamma proteobacteria (e.g. E coli) has 
smallest amino acids such as serine (S), alanine (A) and glycine (G) in this 
position whereas Epsilon and Alpha proteobacteria (which share last 
common ancestor with mitochondria) has asparagine or glutamine. 
Eukaryotes has glutamine exclusively .........................................................  106 
Figure IV-5 Effect of serine to glutamine mutation at position 10 of IscS. (a) Conserved 
histidine interacts with PLP phosphate group. That histidine is hold in 
place by either threonine (dimeric architecture) or glutamine (monomeric 
architecture). (b) Shows the effect of the serine to glutamine switch. 
Towards C-terminus both IscS and NFS1 shows very good alignment. 
After the switch, there is big conformational change in N-terminus. When 
glutamine is the residue interacting with conserved histidine (Purple), the 
conformation that N-terminus adopts would cause collision with some 
residues of the other subunit of IscS (shown in yellow) ..............................  107  
Figure IV-6 Comparison of active sites of IscS and NFS1. The active site looks very 
similar. Most of the residues are identical and they can be aligned in 3D 
very well. Blue, green and red circles pointing towards residues that are 
different between IscS and NFS1 ................................................................  108 
 xvii 
 
Figure IV-7 Comparison of quinonoid decay kinetics. Both D79N and D79N-A106C 
variants shows quinonoid decay kinetics similar to IscS and much faster 
than that of SDAecUF ...................................................................................  109 
Figure IV-8 Comparison of cysteine desulfurase activity. IscSD79N has similar activity 
as wt whereas IscSD79N, A106C has slightly low activity but still much more 
active that SDAec, which has kcat of ~1 per min .........................................  110 
Figure IV-9 Comparison of quinonoid decay kinetics. Both H247P-Q248L and S10Q 
variants shows quinonoid decay kinetics similar to IscS and much faster 
than that of SDAecUF ...................................................................................  111 
Figure IV-10 Comparison of cysteine desulfurase activity. Both IscSH247P, Q248L and 
IscSS10Q has low activity compared to wt. The activity of IscSS10Q is very 
close to that SDAec, which has kcat of ~1 per min ......................................  112 
Figure IV-11 Binding constant determination by dependence of enzyme concentration 
on cysteine desulfurase activity. The data were fitted to Equation (4) to 
obtain binding constants of monomer subunits ...........................................  113 
Figure IV-12 Chromatogram of analytical size exclusion chromatography of IscSS10Q. 
As the protein concentration is lowered, monomer peak (~15.5 mL) grows 
while the dimer peak (~ 14 mL) shrinks indicating a monomer dimer 
equilibrium ...................................................................................................  114 
Figure IV-13 Specific activity correlates well with dimer concentration. Dimer % was 
estimated from analytical size exclusion chromatography. It was then 
plotted against protein concentration along with specific activity. This 
shows dimer concentration dictates specific activity ...................................  115 
 xviii 
 
LIST OF TABLES 
 Page 
Table II-1 Kinetic data for Fe-S assembly complexes (human) ...................................  59  
Table II-2 Rates for individual steps in the cysteine desulfurase reaction for Fe-S 
assembly complexes.....................................................................................  60 
Table III-1 Kinetic data for Fe-S assembly complexes (E. coli) ....................................  92  
Table III-2 Rates for individual steps in the PLP chemistry of cysteine desulfurase ....  93 
Table IV-1 Effect of PLP second shell interacting residues on kcat and quinonoid decay
......................................................................................................................  116 
Table IV-2 Effect of dimer interface residues of IscS on kcat and quinonoid decay ......  117 
 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
IRON SULFUR CLUSTER 
Iron sulfur clusters are one of the most ancient and versatile cofactors found in nature. As 
the name suggests, these cofactors consist of iron and sulfur, more specifically a combination of 
ferrous and ferric irons and sulfide. The iron centers have tetrahedral coordination geometry and 
can bind a maximum of four ligands. Sulfides act as bridging ligand and can occupy 2-3 
coordination sites. The rest of the coordination sites are filled by mostly protein-based ligands 
although small molecule ligand such as glutathione is also known to coordinate iron sulfur cluster. 
Most common of the protein-based ligands are cysteine, which coordinates through side-chain 
thiol. Other less frequently found ligands are histidine (ligation by side-chain imidazole), aspartic 
acid (ligation by side-chain carboxylate), serine (ligation by side-chain hydroxyl group) and even 
α-amino group of amino acids. The simplest of iron sulfur clusters are [Fe2S2] and [Fe4S4], which 
also happens to be the most common type. There are several other forms of iron sulfur clusters, 
which are more complex in nature and found only in a number of proteins. Examples include 
[Fe3S4]
0 (glutamate synthase), [Fe8S7] (P-clusters of nitrogenase), [MoFe7S8C] (M-clusters of 
nitrogenase) and [NiFe3S4] (C-cluster of CODH). However, they are involved in some of the most 
important chemistries found in nature, such as N2 fixation and carbon monoxide oxidation.  
Iron sulfur clusters are redox cofactors capable of adopting multiple redox states and can 
easily perform one or two electron redox reactions. Because of the variety of iron sulfur cluster 
type, they come with a broad range of redox potentials. On one end of the spectrum, we have 
[Fe4S4]
2+/1+ clusters which can be highly reducing (Em = -700 mV). On the other end of the 
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spectrum, we have HiPIPs ([Fe4S4]
3+/2+), which can be highly oxidizing (Em = 400 mV, Ferredoxin 
thioredoxin reductase). Other cluster types have somewhat intermediate redox potential. Redox 
potential of iron sulfur clusters also depends on ligation. For example [Fe2S2]
2+/1+ have more 
reducing having redox potential (in the range of -460 mV to -200 mV) when they are coordinated 
with cysteine. However, in Rieske type cluster where one of the irons is coordinated with two 
histidine residues, the redox potential become more positive and can reach up to +300 mV. Redox 
potential of iron sulfur cluster also depends on solvation and the extent of hydrogen bonding. Both 
bridging sulfides and coordinating irons ligands are excellent candidates for hydrogen bond 
formation, which in turn depends on the extent of solvation. Therefore, mutation of amino acid 
residues near the cluster, complex formation with another protein molecules, substrate binding can 
change the solvation pattern around iron sulfur cluster and in turn change the redox potential of 
the clusters. Redox potential also depends on the geometry of both the cluster and the ligands. Any 
effect that can bring about a conformational change in the protein structure, can change the 
geometry of the ligands and thereby the redox potential of the cluster. All the above points illustrate 
the flexibility and tenability of redox potential of iron sulfur cluster, which makes them ideal 
candidates for the medium of electron transfer process.  
In addition to being excellent in redox chemistry, Iron sulfur clusters can also perform 
several other functions, which are essential for cell viability. For example, iron sulfur clusters can 
function as a catalytic site for substrate binding and activation. In the [Fe4S4] cluster of aconitase, 
three irons are coordinated by three cysteine residues and the remaining iron is coordinated by 
water. This iron (called unique Fe site) provides the coordination site for substrate binding, which 
is followed by dehydration/hydration chemistry. Radical SAM enzymes also provide excellent 
examples of substrate binding by iron sulfur cluster. Here methionine amino acid binds that unique 
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Fe site bidentately via α-amino and α-carboxilato groups. Iron sulfur clusters have also been 
utilized as a mechanism for iron storage. Methanogenic archaea champion this by expressing 
polyferredoxin, which contain up to 12 [Fe4S4] clusters in tandemly repeated 8-Fe ferredoxin like 
domain1-2. Iron sulfur clusters are also used as a substrate. Examples include biotin biosynthesis, 
lipoic acid biosynthesis. Iron sulfur clusters especially [Fe4S4] are very susceptible towards 
oxidative damage, which degrades them primarily to [Fe2S2]. This usually is accompanied by a 
large conformation change. This property has been utilized by proteins to act as a sensor of 
oxidative stress (example FNR). All these make iron sulfur cluster one of nature’s most versatile 
and important cofactor. 
 
BIOSYNTHETIC PATHWAYS OF IRON SULFUR CLUSTER 
NIF pathway 
In earlier days of evolution, the world used to be anaerobic and iron and sulfur were 
abundant in their reduced form (ferrous iron and sulfide). This vast pool of sulfide and ferrous iron 
were probably utilized to make iron sulfur clusters. However, this process is not efficient. It 
requires a lot of material and the production of the desired iron sulfur cluster cannot be controlled. 
Under laboratory conditions, the combination of ferric iron with sulfide often leads to a much 
larger polymeric species with an unspecific stoichiometry of iron and sulfur. This polymeric 
species is not soluble and therefore if produced, will be deposited in the cell and this, in turn, will 
interfere with the normal cellular process. It is no surprise that a biosynthetic mechanism has 
evolved, which will give rise to desired iron sulfur cluster species under controlled conditions with 
minimum side products.  
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Iron sulfur cluster biosynthesis machinery was first identified in nitrogen-fixing bacterium 
Azotobacter vinelandii. A systematic analysis of the genes co-expressed with the structural 
components (nifH, nifD, nifK) of nitrogenase led to the discovery of the nitrogen-fixation-specific 
(nif) gene cluster (nifUSVWZM)3-4. Later on, inactivation of individual genes in the nif gene 
cluster led to a very interesting observation. Except for nifU and nifS, all other gene inactivation 
resulted in defects of either P-cluster or M-cluster. However, deletion of either nifU or nifS caused 
a substantial loss of activity of both P-protein and MoFe-protein. As both P-cluster and M-cluster 
are more complex iron sulfur cluster, it was concluded that both NifU and NifS function in the 
formation of small and simple iron sulfur clusters unit, which then can be combined by P-cluster 
and M-cluster specific maturation genes to produce P-cluster and M-cluster respectively5. 
Subsequent purification and biochemical analysis revealed that (1) NifS contains PLP cofactor, 
(2) NifS takes up L-cysteine as substrate and produces L-alanine and under reducing conditions 
also produces sulfide, (3) an active site cysteine is essential for its activity, mutation or alkylation 
of this cysteine leads to inactivation of the enzyme and (4) it contains persulfide after incubation 
with cysteine. This led to the conclusion that NifS catalyzes desulfurization of cysteine and hence 
NifS was termed as cysteine desulfurase. Similar biochemical analysis of NifU revealed that it can 
accommodate the formation of a transient iron sulfur cluster and thereafter designated as scaffold 
protein6.  
 
ISC pathway 
  The incomplete loss of nitrogenase activity upon deletion of NifS and NifU suggested that 
there might be some house-keeping iron sulfur cluster biosynthetic pathway operating at a very 
slow rate under nitrogen-fixing condition. Therefore, a search under non-nitrogen-fixing 
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conditions with nifS deleted strain led to the discovery of another cysteine desulfurase. Further 
genetic experiments7 revealed that this newly found cysteine desulfurase gene is a part of an 
operon8, which was named as ISC (Iron Sulfur Cluster) operon indicating their involvement in iron 
sulfur cluster biosynthesis pathway7. This operon contained nine genes, now designated as cysE2, 
IscR, IscS, IscU, IscA, hscB, hscA, fdx and iscX. Except for cysE2, expressions of all other genes 
are regulated by iscR. Subsequent biochemical and genetic studies demonstrated that isc genes are 
involved in the biosynthesis of iron sulfur clusters in general9 and thereby act as a housekeeping 
system. IscR turned out to be a transcription regulator that regulates the expression of all the genes 
in isc operon including itself except cysE2. CysE2 was found to be involved in cysteine 
biosynthesis and separately regulated. IscS is a PLP dependent cysteine desulfurase10 that bears 
considerable sequence identity with first identified cysteine desulfurase NifS. IscU has a high 
sequence similarity with the first domain of NifU and acts as a scaffold protein. IscA has been 
postulated to be an alternate scaffold11 and a site for converting two [Fe2S2] clusters into [Fe4S4] 
cluster by two-electron reduction coupling12-15. HscB and HscA share sequence identity with DnaJ 
and DnaK, which acts as chaperon. This prompted to hypothesize that HscB and HscA might act 
as co-chaperon and chaperon respectively and helps in cluster delivery to target protein by bringing 
about a conformational change in either cluster bound IscU or apo-target protein in an ATP 
dependent manner16-18. Interestingly isc operon encodes for fdx gene19 that expressed a [Fe2S2] 
containing ferredoxin, which has been shown to be essential and speculated to take part in electron 
delivery during iron sulfur cluster biosynthesis. IscX has been shown to inhibit iron sulfur cluster 
biosynthesis and may have some regulatory role. Later on, genome-wide search revealed isc 
operon to be a part of many other bacterial genomes, solidifying its role as the housekeeping iron 
sulfur cluster biosynthetic pathway. 
 6 
 
 
SUF pathway 
 Consistent with their housekeeping role, deletion of IscS and IscU in Azotobacter 
vinelandii proved to be fatal. However, when IscS and IscU were deleted, the resulting strain of E. 
coli remained viable. This observation led to the discovery of another iron sulfur cluster 
biosynthesis pathway, called SUF system (Sulfur Utilization Factor). In E. coli suf operon consist 
of sufA, sufB, sufC, sufD, sufS and sufE. SUF system was found to be involved in biosynthesis, 
protection and repair of iron sulfur clusters under the condition of oxidative stress or iron 
starvation. 
 
IRON SULFUR CLUSTER BIOSYNTHETIC PATHWAYS IN EUKARYOTES 
 In eukaryotes, iron sulfur cluster assembly takes place mainly in mitochondrial matrix 
space and involves about 10 proteins. The members of this pathway are – NFS120, ISD1121, ACP, 
ISCU2, FXN, FDX222, FDXR23, HSC2024, HSP75, GRX5, ISCA1/225 and ABC720, 26. Most of 
these proteins bear high sequence identity to the proteins encoded by bacterial isc operon and 
therefore this mitochondrial iron sulfur cluster biosynthetic pathway was defined as ISC pathway. 
The genes involved in this process are nuclear encoded and imported into mitochondria using 
mitochondrial-targeting sequence (MTS) as a guide. Proteins first get unfolded and enter 
mitochondria. MTS is then cleaved by mitochondrial processing peptidases and the resultant 
mature proteins are folded back to their active form in a chaperon-mediated pathway. As expected, 
mitochondrial ISC pathway is more complex than bacterial and involves several eukaryotic 
specific proteins or proteins of bacterial origin that now has a new function.  
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NFS1 is the cysteine desulfurase27 required in this process. It is a 47 kD homo-dimer and 
bears 59% sequence identity with E. coli IscS. It contains a PLP cofactor and reacts with cysteine 
as substrate to produce alanine and a persulfide on the active site cysteine, which is situated on a 
mobile loop. NFS1 by itself is very unstable and readily precipitated when recombinantly 
expressed in E. coli. ISD11 is a three-helix bundle eukaryotic specific protein with a molecular 
weight of 11 kD. It is positively charged at physiological pH (estimated pKa = 10.73) and has 
conserved Leucine-Tyrosine-Arginine (LYR) motif at the N-terminus, which makes it a member 
of the LYR family of proteins. Knockout and knockdown studies confirmed that ISD11 is 
essential21, 28-29 for viability and has function in mitochondrial iron sulfur cluster biosynthetic 
pathway. It forms a stable complex with NFS1, called SD (NFS1 + ISD11) and has been proposed 
to stabilize NFS1. Additionally, ISD11 has also been proposed to activate the mobile loop cysteine 
on NFS130-32. Acyl Carrier Protein (ACP), a small 10 kD protein known for its requirement in type 
II fatty acid synthesis (FAS), has recently been characterized to have a moonlighting function in 
iron sulfur cluster biosynthesis through complex formation with NFS1 and ISD11 with a final 
stoichiometry of 1:1:1. This three-protein complex SDA (NFS1 + ISD11 + ACP) has been 
characterized as the functional cysteine desulfurase unit for iron sulfur cluster biosynthesis. ACP 
has a 4’-phosphopentethiene (4’-PPT) prosthetic group covalently bound to a conserved serine 
residue. This 4’-PPT forms a thioester linkage with fatty acid during fatty acid synthesis (FAS). In 
the crystal structure of SDA complex, a 16-carbon long fatty acid covalently bound to ACP through 
4’-PPT was found to be inserted into the hydrophobic core of ISD11 created by the unusual 
conformation of the three helixes. At the end of this hydrophobic core, there is a conserved 
phenylalanine residue that is connected to the active site of NFS1 through hydrogen bonding. It 
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was proposed that ACP might regulate iron sulfur cluster biosynthesis by regulating cysteine 
desulfurase activity by varying the chain length of the bound fatty acid33.  
ISCU2 is the scaffold protein, which is 70% identical with E. coli IscU. ISCU2 has three 
cysteine residues (C35, C61 and C104) which are conserved in all organisms and required for 
coordination with the [Fe2S2]. ISCU2 binds with SDA in 1:1 stoichiometry to form SDAU 
complex. 
There are two A-type proteins in human mitochondria, ISCA1 and ISCA2, which function 
in maturation of [Fe4S4] along with IBA57 (Iron sulfur cluster assembly factor for biotin synthase 
and aconitase-like mitochondrial protein, molecular weight 57 kD)34-35. ISCA2 is similar to ISCA1 
except a 21-residue insert, which makes their function non-redundant. E. coli homolog IscA can 
complement for ISCA1 but not for ISCA2. ISCA has also been shown to bind one iron (0.86 ± 
0.24) per dimer with an association constant of at least 2 x 1019 M-1, which is comparable with E. 
coli IscA (1 x 1019 M-1) and human transferrin (4.7 x 1020 M-1)36-37.  
HSP70 and HSC20 are homologous to E. coli HscA and HscB respectively. This 
chaperon/co-chaperon system has been shown to accelerate [Fe2S2] transfer from ISCU2 to GRX5. 
However, details of this transfer process is still unknown. GRX5 is a monothiol glutaredoxin 
homologous to Grx4 in E. coli and has been shown to act as an intermediate during iron sulfur 
cluster delivery to different apo-acceptor. ABC7 is an ABC transporter, specific to eukaryotes and 
absolutely critical for cell viability, is present in the mitochondrial outer membrane. It has been 
postulated that it acts as a gate for an unknown sulfur compound, which needs to be released from 
mitochondria into the cytosol for further iron sulfur biosynthesis process, known as CIA pathway. 
Although postulated as a second iron sulfur cluster biosynthetic pathway in eukaryotes, its 
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dependence on mitochondrial pathway raises question if the CIA pathway should be considered a 
separate pathway or an extension of mitochondrial ISC pathway. 
 
FRIEDREICH’S ATAXIA (FRDA) AND FRATAXIN  
 Friedreich’s ataxia (also called FRDA) is an autosomal recessive neurodegenerative 
disorder and most common form of ataxia. It has been estimated in Europe one in 50,000 people 
suffer from this disease and one in every 120 people are deduced carrier. Symptoms of this disease 
include gait, limb ataxia, lack of tendon reflexes and sense of position and hypertrophic 
cardiomyopathy. Symptoms first appear usually around puberty and by the age of 20 the patient 
becomes confined in a wheelchair and wait for a slow and painful death, as there is no cure. A 
gene called X25 was identified at chromosome 9q13 –q21.1, had an abnormally long GAA triplet 
repeats in the first intron and impaired transcription profile most likely because of the abnormal 
intronic expansion. This gene contained 5 exons and encoded 210 amino acid proteins, which was 
named frataxin38. Normally there are 7-40 repeats of GAA triplet. However, for some FRDA 
patients the repeat can reach up to 1700.39 It was later established that the number of repeats 
inversely correlated with expression levels of the protein frataxin.40 Larger the repeat, lower is the 
expression. This confirmed that loss of frataxin would cause FRDA. More than 95% FRDA patient 
are homozygous i.e. both the allele contains abnormal GAA triplet repeat. However, a small 
fraction of FRDA patient patients were found to be heterozygous i.e. one allele contains 
abnormally GAA triplet repeat and the other allele contains missense or nonsense mutation41. 
This breakthrough in FRDA research led to extensive biochemical characterization of the 
frataxin gene. First by tagging a GFP protein, frataxin was found to be targeted towards 
mitochondria42. Expansion of this study to human, mouse and yeast revealed frataxin function in 
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mitochondria and this is universal phenomenon43. Proteins targeted to mitochondria generally 
contain a highly arginine and lysine-rich positively charged targeting sequence. Amino acid 
sequence revealed that frataxin also has one and it is 55 amino acids long. After frataxin enters 
mitochondria, the first 40 residues of this mitochondrial targeting sequence are cleaved by a 
mitochondrial processing peptide (MPP)44. The resultant polypeptide (41 – 210) undergoes a 
second truncation step to yield the final mature form, which contains residues 82 – 21045-47. This 
mature form is however unfolded during mitochondrial entry and efficiently refolded with the help 
of Tim44 and mtHSP70 proteins48.  
Function of frataxin and its involvement in FRDA has been the center of debate for a long 
time. Frataxin has been proposed to be a regulator of iron homeostasis in mitochondria as its 
deletion resulted into severe impairment of iron flux49-50. Excessive iron accumulation in 
mitochondria in frataxin-deleted strains led to the proposal of frataxin being an iron storage 
protein51. Genome-wide analysis of gene expression has shown frataxin deficiency results in 
elevated levels of proteins, especially iron uptake proteins that are under control of iron sensing 
transcription factors such as ATF1/ATF252-54. The fact that these transcription factors are induced 
under low cytosolic iron condition led to the proposal that frataxin is involved in maintaining the 
efflux of iron from mitochondria into cytosol. One common side effect of excess iron accumulation 
in frataxin-deficient cells has been damaged by reactive oxygen species (ROS). Therefore, frataxin 
has also been proposed to have a function in ROS detoxification55-56. Frataxin deficiency also 
resulted in deficiency of mitochondrial iron sulfur protein such as aconitase57. However, as it was 
known that ROS could damage aconitase [Fe4S4] cluster, it was not known for sure if the 
deficiency in iron sulfur protein was because of oxidative damage from ROS or because absence 
of frataxin impaired. Later on, it was conclusively shown that indeed frataxin play an important 
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role in iron sulfur cluster biosynthesis in mitochondria58-60 and all other phenotype could be 
explained by this. Iron-binding properties of yeast frataxin61 and impaired iron homeostasis in 
frataxin-deficient mitochondria later led to the proposal of frataxin being iron chaperon62-63 and 
iron donor64 during iron sulfur cluster biosynthesis. However, iron binding of frataxin is not 
stoichiometric and depending on the source, frataxin can bind 0-16 iron suggesting iron binding 
can be an artifact of the carboxylic acid patch of frataxin64-67. Indeed, iron donor and iron storage 
role of frataxin is later refuted convincingly68. 
A paradigm shift in frataxin function discovery occurred when frataxin was found to form 
a complex with cysteine desulfurase complex (SDA) in presence of ISCU269-71 and act as an 
allosteric activator70 of the cysteine desulfurase72. Frataxin were able to accelerate the rate of 
cysteine desulfurase activity by 5 times and in the presence of ferrous iron, the rate went up to 
about 10 times. In vitro iron sulfur cluster formation assay showed an equivalent acceleration for 
SDAUF complex compared to SDAU, establishing acceleration of cysteine desulfurase activity by 
frataxin was sufficient to explain the role of frataxin in iron sulfur cluster biosynthesis. Later on, 
it was found that frataxin variants found in FRDA patients had weaker binding to cysteine 
desulfurase complex and also failed to accelerate cysteine desulfurase activity to same extent as 
wild-type frataxin73-74. This further solidified frataxin’s function as an allosteric activator. 
However, about same time frataxin homolog in E. coli CyaY were found to an inhibitory effect on 
iron sulfur cluster biosynthesis despite not having any impact on cysteine desulfurase activity75. 
This puzzle was solved after a very interesting discovery that acceleration or inhibition by 
frataxin/CyaY was dependent on the cysteine desulfurase76. So, with IscS both CyaY and frataxin 
inhibited iron sulfur cluster biosynthesis whereas with SDAU, both CyaY and frataxin accelerated 
iron sulfur cluster biosynthesis. To account for the allosteric activator function of frataxin research 
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was focused in mainly two areas – 1) it was tested if frataxin can accelerate persulfide formation 
on the mobile loop cysteine of NFS1 and 2) if frataxin can accelerate the transfer of sulfane sulfur 
from mobile loop cysteine of NFS1 to ISCU2 or small molecule thiols. Cysteine binding ability of 
the active site PLP was tested in presence and absence of frataxin and it was found that frataxin 
increased the amount of cysteine bound to PLP and thereby concluded that frataxin facilitates 
cysteine binding to the active site31. It has also been proposed that frataxin helps orienting the 
mobile loop of NFS1 and thereby accelerate C-S bond cleavage of the cysteine substrate, which in 
turn results in increased rate of persulfide generation on mobile loop cysteine. However, any kind 
evidence has not been presented till date in support of the above-mentioned hypothesis. Evidence 
for frataxin’s function as accelerator of sulfur transfer first emerged when radioactive 35S was 
incubated with SDAUF and found increased radioactivity on ISCU277. However, presence of 
excess thiol which can act as sulfur transfer agent and increased radioactive labeling on NFS1 
raised doubt if enhanced radioactive labeling on ISCU2 is because of acceleration of sulfur transfer 
step or as a downstream effect of enhanced cysteine desulfurase activity. Later on, similar result 
was obtained in another elegant study. However, the extent of increase in persulfide content on 
ISCU2 compared to NFS1 clearly showed that it could not be explained by acceleration of cysteine 
desulfurase activity alone and frataxin must accelerate sulfur transfer step78. The same study also 
showed accelerated reduction of NFS1 persulfide by DTT in presence of frataxin78. Therefore, it 
was concluded that frataxin accelerates iron sulfur cluster biosynthesis by accelerated release of 
sulfide which is utilized in making iron sulfur cluster. After all these years of rigorous research, 
still there has not been a unanimous conclusion about the function of frataxin. 
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FRATAXIN BYPASS 
 Frataxin function discovery drew a considerable attention of the scientific community 
mostly because of the prospect of drug discovery for Friedreich’s Ataxia. A serendipitous 
discovery of a variant of Isu protein in yeast, which could alleviate the phenotype of frataxin 
deletion in absence of frataxin, also became very interesting.  While experimenting with a frataxin-
deleted yeast strain, it was observed that some of the colonies out-grew others. A followed-up 
detailed genetic analysis revealed that a single amino acid residue (M107) on Isu underwent a 
spontaneous mutation to different amino acids such as isoleucine, leucine, and valine and that 
single mutation was responsible for the observed frataxin bypass phenomena79. It was later shown 
in an in vitro experiment that M107I variant of Isu in yeast could increase cysteine binding to PLP, 
just like frataxin31. This gave rise to the hypothesis that M107I variant of Isu (M106I in human 
ISCU2) acts like frataxin and can replace frataxin. Frataxin was hypothesized to cause a 
conformational change in wild-type ISCU2 that activated cysteine desulfurase and M106I variant 
of ISCU2 was postulated to be already in that conformation and therefore activated cysteine 
desulfurase even in absence of frataxin.  
 
MECHANISM OF IRON SULFUR CLUSTER BIOSYNTHESIS 
 Although we have a pretty good idea about the functions of the proteins involved in iron 
sulfur cluster, there is not much known about the chemistry that happens during iron sulfur cluster 
biosynthesis. We know cysteine reacts with the PLP cofactor of NFS1 to generate a persulfide on 
the mobile loop cysteine. A mechanism of cysteine desulfurase activity had been proposed based 
on the work with NifS. However, no further work has been done to prove or disprove that 
mechanism. It is well known with PLP-dependent enzymes that amino acid residues surrounding 
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PLP cofactor play important role in protonation and deprotonation of PLP that has a profound 
effect on the activity of the enzyme. No systematic analysis of residues in cysteine desulfurase has 
been done to evaluate their effect on cysteine desulfurase activity, which in turn could help to 
figure out the exact mechanism of cysteine desulfurase activity.  
 There has been a considerable amount of debate whether or not sulfur transfer from NFS1 
mobile loop cysteine to ISCU2 is actually a part of iron sulfur cluster biosynthesis pathway. ISCU2 
has their conserved cysteines – C35, C61 and C104 (C37, C63 and C106 in E. coli IscU). Evidence 
has been produced for all three cysteines residue to be the acceptor of sulfane sulfur by different 
groups77, 80-81. Not only that, these cysteine residues were shown to contain polysulfide. However, 
all the experiments were carried out in excess of cysteine. Therefore, the observations could be 
explained by a thiol-mediated sulfur transfer event where cysteine (or other small molecule thiols) 
can cleave NFS1 persulfide to generate cysteine persulfide, which now can distribute that sulfane 
sulfur to any available thiol. The finding that frataxin can accelerate sulfur transfer to small thiols 
such as DTT even led to the proposal that thiol-mediated sulfur transfer is actually the 
physiological way if iron sulfur cluster biosynthesis78. However, DTT being a non-physiological 
molecule raised the possibility than this is a DTT dependent phenomena and physiological thiol 
such as cysteine and glutathione may behave differently. Also, so far nobody has demonstrated 
under similar condition using physiological thiol one pathway is faster that other one. There had 
been another debate on whether or not the iron sulfur cluster biosynthesis followed iron-first 
mechanism or sulfur first mechanism i.e. whether ISCU2 obtains the sulfur before it binds iron 
(sulfur-first) or after it binds iron (iron-first). The fact that elevated levels of persulfide is formed 
on ISCU2 in presence of frataxin and in absence of iron settled the debate in favor of sulfur-first 
mechanism77.  
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 [Fe2S2] gets both sulfurs from cysteine via a persulfide intermediate on NFS1. To generate 
two sulfide molecules from two persulfides requires four electrons. Since ferrous iron is used as 
substrate82 and in the final cluster it is found in +3 oxidation state, we can assume that two of the 
required four electrons come from two ferrous irons. The source of the remaining two electrons 
has not been conclusively proven. Ferredoxin (both in E. coli and yeast) has been shown to be 
required for iron sulfur cluster biogenesis22, 83-85. Therefore, it was postulated that ferredoxin along 
with ferredoxin reductase and NADPH delivers the remaining two electrons. Evidence has been 
provided with both E. coli and human system in support of electron donating ability of NADPH-
ferredoxin reductase-ferredoxin system85-86. However, the overall rate and the amount of [Fe2S2] 
bound ISCU2 produced in that reaction has been very small when compared with thiols (cysteine 
or glutathione) as reducing system. Chemically reduced ferredoxin (both in E. coli and human) has 
also been shown to be able to reduce persulfide on the mobile loop cysteine of cysteine 
desulfurase87-88. One would expect a stoichiometric transfer of electrons from reduced ferredoxin 
to persulfide to generate sulfide i.e. one equivalent of sulfide production from two equivalents of 
reduced ferredoxin. However, the experiment generated much more sulfide than one would expect 
from the amount of reduced ferredoxin used. Also, this experiment did not provide any account of 
what happens to ISCU2 persulfide up on treatment with reduced ferredoxin. In a different 
experiment, using a novel gel-based assay to detect persulfide bound to protein, reduced ferredoxin 
was shown not to be able to cleave persulfide on both NFS1 and ISCU278. Additionally, ferrous 
iron alone and together with reduced ferredoxin also failed to reduce persulfide on both NFS1 and 
ISCU278.  
 Another unknown, related to the mechanism of iron sulfur cluster biosynthesis is the 
stoichiometry of ISCU2 when it has a [Fe2S2] cluster. ISCU2 has been shown to exist as a monomer 
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or dimer with one [Fe2S2] cluster per monomer or dimer respectively
89. ISCU2 dimer has also been 
proposed to be the physiological iron sulfur cluster source for all iron sulfur protein in 
mitochondria although the evidence is weak. The major problem with the idea of ISCU2 monomer 
as a scaffold is the lack of a fourth ligand. All of the conserved cysteines have been shown through 
mutational analysis to be essential for iron sulfur cluster synthesis on ISCU2 and therefore they 
were hypothesized to form three of the four available coordination to [Fe2S2] cluster. Different 
residues had been proposed as the fourth ligand, which includes H107, D37 and even the mobile 
loop cysteine of cysteine desulfurase90. The fact that the D37A mutation on IscU produces an even 
more stable cluster rule out D37 as the fourth ligand91. Resonance Raman analysis of [Fe2S2] bound 
IscU showed a higher stretching frequency than normally found for thiol (cysteine) ligation. It was 
interpreted, as the fourth ligand must be smaller than sulfur i.e. either oxygen or nitrogen. H107 is 
in proximity and can ligate through imidazole side chain. However, if imidazole coordinates, the 
stretching frequency will be even lower as the whole imidazole moiety acts as a single unit and 
not just a nitrogen atom92. Considering proximity to the cluster oxygen ligation is the only 
explanation for the fourth ligand. However, no such residue has been identified to date that fits 
these criteria. 
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CHAPTER II                                                                                                                
MECHANISM FOR ACTIVATION AND BYPASS OF FRATAXIN IN HUMAN FE-S 
CLUSTER BIOSYNTHESIS 
 
 
INTRODUCTION 
Iron sulfur (Fe-S) clusters are ubiquitous protein cofactors that are required for critical 
cellular processes 93-94. Fe-S clusters exist in a variety of stoichiometries, most often as [2Fe-
2S]2+/1+ and [4Fe-4S]2+/1+ species, and commonly function in substrate activation and in electron 
transfer. Fe-S clusters are synthesized and distributed to apo target proteins by conserved 
biosynthetic pathways. In humans, an assembly complex located in the mitochondrial matrix is 
responsible for synthesizing Fe-S clusters. The structural core of this assembly complex consists 
of cysteine desulfurase (NFS1), eukaryotic-specific LYR protein (ISD11), and acyl carrier protein 
(ACP) subunits and is referred to as the SDA complex 33, 95. The ISD11 and ACP subunits are 
required for function, stabilize NFS1, and favor different quaternary interactions for NFS1 than its 
prokaryotic homologs 33, 96-99. NFS1 uses a pyridoxal 5’-phosphate (PLP) to convert L-cysteine to 
L-alanine and generate a persulfide intermediate on a cysteine residue of a mobile S-transfer loop 
(Figure II-1, step 1). Sulfur is then transferred from NFS1 to a cysteine residue on the scaffold 
protein ISCU2 (Figure II-1, step 2). ISCU2 combines sulfane sulfur with Fe2+ and electrons to 
produce [2Fe-2S]2+ clusters 72, 77, 100 (Figure II-1, step 3) in a poorly understood process. To 
complete catalytic turnover, intact [2Fe-2S] cluster intermediates on ISCU2 are transferred to a 
cluster carrier protein, such as the monothiol glutaredoxin GRX5 (Figure II-1, step 4), as a part 
of the cluster distribution network. 
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Although eukaryotes require frataxin (FXN) for the synthesis of Fe-S clusters 59, 101-102, the 
precise role of FXN remains controversial. The loss of FXN is linked to the fatal neurodegenerative 
disease Friedreich’s ataxia (FRDA) 103, which results in decreased activity for Fe-S cluster 
enzymes, accumulation of iron in the mitochondria, and susceptibility to oxidative stress 50, 104. 
Identifying the role of FXN has been complicated by the existence of isoforms of different lengths. 
The longer form, FXN1-55, can undergo an iron-dependent oligomerization to produce a species 
reminiscent of ferritin that may function in iron storage 105-109. The truncated form, FXN1-80, is 
widely considered to be the functional form in vivo; truncated FXN is monomeric even in the 
presence of iron 110, interacts with the NFS1-ISD11-ISCU2 complex 70, 72, 102, 111-112, and rescues 
cells challenged with FXN depletion 113. Early studies revealed that FXN1-80 has a modest binding 
affinity for iron (3-55 µM) and led to the proposal that FXN accelerates Fe-S cluster synthesis by 
functioning as a chaperone that donates iron 61-63, 112, 114-119. More recently, multiple studies provide 
evidence that FXN functions as an allosteric activator that enhances cysteine desulfurase activity 
and the subsequent rate of Fe-S cluster assembly on the scaffold protein 31, 70, 72, 77, 120. FXN has 
been proposed to affect the sulfur chemistry by enhancing cysteine binding to the PLP cofactor of 
the cysteine desulfurase 31, and increasing sulfur transfer to the scaffold protein 77, 120 and small 
molecule thiols 70, 120. Conflicting results indicate that FXN does 31, 77 or does not 120 affect 
persulfide formation on NFS1. Interestingly, a suppressor mutant on Saccharomyces cerevisiae 
Isu1 (homolog of human ISCU2; Isu1M107I also known as Isu1Sup) was identified that rescues the 
depletion of S. cerevisiae Yfh1 (homolog of human FXN) 79, 121. Initial studies have suggested that 
Isu1M107I increases the accumulation of persulfide species on Nfs1 similar to the addition of FXN 
31, 77; however, additional kinetic studies are required to probe details of the mechanism and 
 19 
 
determine the specific chemical steps FXN and Isu1M107I accelerate in promoting Fe-S cluster 
biosynthesis. 
In this manuscript, new assays were developed to probe how FXN and human ISCU2M106I 
(equivalent to Isu1M107I) affect the kinetics of individual steps in Fe-S cluster biosynthesis. We 
found that the addition of either FXN or substitution of ISCU2 with ISCU2M106I increased the 
overall rate of cluster synthesis and transfer to GRX5. Further, these studies provide compelling 
evidence that FXN accelerates reactions involving the NFS1 mobile S-transfer loop that result in 
an increased rate of [2Fe-2S] cluster assembly on ISCU2. In contrast, ISCU2M106I primarily affects 
the transfer rate of intact [2Fe-2S] clusters from ISCU2 to GRX5. Overall, our results provide new 
mechanistic insight into Fe-S cluster biosynthesis and indicate FXN and ISCU2M106I function at 
distinct stages of this pathway. 
 
RESULTS 
Both the ISCU2M106I substitution and FXN accelerate the formation of [2Fe-2S] clusters on 
GRX5. Our initial objective was to test if the substitution of human ISCU2 with the ISCU2M106I 
variant functions analogously to FXN and stimulates Fe-S cluster biosynthesis.  A circular 
dichroism (CD) assay was developed to monitor an entire Fe-S cluster assembly and transfer 
reaction (Figure II-1, step 1-4) to better reproduce the in vivo biosynthetic pathway than 
previously reported assays that only monitor partial reactions. This assay takes advantage of the 
positive ellipticity from [2Fe-2S]-GRX5 and low ellipticity from [2Fe-2S]-ISCU2 at 450 nm 
(Figure II-2). The reaction conditions contained the recombinantly expressed human NFS1-
ISD11 complex that co-purified with Escherichia coli ACP (SDAec) 
33, 122, with the addition of 
recombinant human ISCU2 (SDAecU), ISCU2
M106I (SDAecU
M106I), or ISCU2 and FXN 
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(SDAecUF). Reactions were initiated with the addition of L-cysteine and glutathione, which is 
required for binding the Fe-S cluster to GRX5. All complexes exhibited final CD spectra consistent 
with [2Fe-2S]-GRX5 (Figure II-3). Similar overall rates were observed for the SDAecUF and 
SDAecU
M106I complexes (Fig. II-4A and Table II-1), which were about 3 times greater than the 
SDAecU complex. The results from this in vitro Fe-S cluster biosynthetic assay are consistent with 
both the stimulation of activity by FXN and the bypass of FXN by ISCU2M106I. 
 
FXN and ISCU2M106I operate at different steps in Fe-S cluster biosynthesis. We tested the 
effect of adding FXN to the SDAecU
M106I complex in complete cluster assembly and transfer 
reactions (Figure II-1, step 1-4). The SDAecU
M106IF complex had a rate that was faster than 
SDAecU (nearly 7-fold greater) and was about twice the rate of either the SDAecUF or SDAecU
M106I 
complex (Fig. 1A and Table II-1). This additive result in the Fe-S assembly assay hints that the 
stimulatory effects of FXN and ISCU2M106I occur at different steps in Fe-S cluster biosynthesis. 
As FXN was previously shown to increase the rates of partial reactions, including the Fe-S cluster 
assembly reaction on ISCU2 and the cysteine desulfurase activity of SDAecU 
33, 70, 123, we tested 
whether ISCU2M106I also affected those steps of Fe-S cluster biosynthesis. 
The ISCU2M106I variant was tested for its ability to mimic FXN and increase the rate of 
[2Fe-2S] cluster formation on ISCU2 (Figure II-1, step 1-3). We used CD to monitor [2Fe-2S] 
cluster formation on ISCU2 and ISCU2M106I by following changes in ellipticity at 330 nm, similar 
to a previously reported assay 123. Here, the addition of FXN to the SDAecU complex was shown 
to accelerate Fe-S cluster formation on ISCU2 (2.8 fold greater) under a comparable set of 
conditions (Figure II-4B and Figure II-5; Table II-1). The SDAecU
M106I complex exhibited 1.5 
times greater cluster synthesis activity compared to the native SDAecU complex, but only about 
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half the activity of SDAecUF. Addition of FXN to the SDAecU
M106I complex further enhanced the 
activity (1.5 fold greater), consistent with FXN stimulation of the native system. 
We also tested the effect of substituting the ISCU2M106I variant for ISCU2 in cysteine 
desulfurase activity assays. SDAec was previously shown to exhibit a low kcat (0.60 min
-1) for the 
cysteine desulfurase reaction 33, which was not affected by the addition of ISCU2, but showed a 
stimulation by an order of magnitude upon the addition of both ISCU2 and FXN (Table II-1) 33, 
70. The SDAecU
M106I complex exhibited kinetic parameters highly similar to the SDAecU complex 
with a kcat 10-fold lower than the SDAecUF complex (Table II-1 and Figure II-6). Moreover, the 
addition of FXN to the SDAecU
M106I complex stimulated kcat in a manner reminiscent of the wild-
type system. Overall, the additive effect in the complete synthesis and transfer assays coupled to 
the inability of ISCU2M106I to replace FXN in partial Fe-S cluster assembly and cysteine turnover 
reactions are consistent with FXN and ISCU2M106I affecting different steps of Fe-S cluster 
biosynthesis. 
 
The ISCU2M106I substitution accelerates cluster transfer to GRX5. Since ISCU2 acts as a 
scaffold for [2Fe-2S] cluster synthesis and functions as an intermediate to transfer these clusters 
to target proteins, we evaluated the ability of FXN and ISCU2M106I to affect the transfer of the 
[2Fe-2S] cluster intermediate from ISCU2 to GRX5 (Figure II-1, step 4). The SDAecU and 
SDAecU
M106I complexes were incubated with L-cysteine and ferrous iron in the absence of GRX5 
and the development of the characteristic [2Fe-2S]-ISCU2 CD spectrum was observed (Figure II-
7). After completion of the [2Fe-2S]-ISCU2 formation reaction, apo-GRX5 (with or without FXN) 
was added under anaerobic conditions, and the cluster transfer reaction from ISCU2 to GRX5 was 
followed by monitoring the increase in ellipticity at 450 nm (Figure II-4C and Figure II-8). The 
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rates of cluster transfer for the native complex with and without FXN were the same within error 
(Table 1), establishing that FXN does not have a role in cluster transfer under these conditions. In 
contrast, Fe-S assembly complexes containing the ISCU2M106I substitution almost doubled the rate 
of cluster transfer to GRX5 compared to those with wild-type ISCU2.  
Next, we tested whether the dissociation of [2Fe-2S]-ISCU2 or [2Fe-2S]-ISCU2M106I from 
the SDAec complex, which is thought to be necessary to facilitate cluster transfer, impacts cluster 
exchange reactions with GRX5. Fe-S clusters were chemically reconstituted on ISCU2 and 
ISCU2M106I in the absence of the SDAec complex. After purification, ISCU2 and ISCU2
M106I each 
bound approximately two iron atoms and two sulfide atoms per protein. The [2Fe-2S]-bound 
proteins were reacted with GRX5 and shown to have similar initial kinetics but different overall 
extents of transfer (Figure II-4D and Figure II-9). The ellipticity change for ISCU2M106I was 
approximately 4 times greater than that for native ISCU2, suggesting that the ISCU2M106I 
substitution alters the cluster-binding equilibrium compared to native ISCU2 and favors the 
cluster-bound GRX5 species. One possible explanation for this result is that the [2Fe-2S] cluster 
bound to ISCU2M106I is less stable leading to enhanced transfer to GRX5. To test this possibility, 
a DTT extrusion assay was used to examine the susceptibility of ISCU2 and ISCU2M106I to loss of 
their [2Fe-2S] clusters. [2Fe-2S] clusters were enzymatically generated on ISCU2 (or ISCU2M106I) 
and the proteins were combined with DTT (Figure II-10). Both samples lost a majority of their 
cluster-dependent CD signal within 30 min. The similar rates of cluster loss (within 15% of one 
another; Figure II-10A) indicates the much greater extent of [2Fe-2S] cluster transfer from the 
ISCU2M106I sample to GRX5 (Figure II-4D) involves more than just a change in cluster stability. 
Overall, these studies indicate that the ISCU2M106I substitution, but not FXN, affects the Fe-S 
cluster transfer reaction from ISCU2 to GRX5. 
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FXN accelerates persulfide formation on NFS1 and ISCU2. Our next objective was to further 
define how FXN accelerates Fe-S cluster synthesis. To probe the effect of FXN on the rates of 
sulfur accumulation on NFS1 and ISCU2 (Figure II-1, step 1 & 2), a rapid acid quench assay was 
developed that couples HPLC separation with radiolabeled sulfur detection. In this assay, various 
Fe-S assembly complexes are reacted with L-[35S]-cysteine substrate, quenched with acid after 
different reaction times, and applied to a reverse phase HPLC column for analysis of protein 
content (absorbance) and persulfide label (radioactivity). The ability to rapidly protonate thiolate 
nucleophiles, which inhibits sulfur transfer reactions 124, and analyze proteins for 35S incorporation 
under quench conditions are critical aspects of this assay. Control experiments established 
conditions to separate proteins in the SDAecUF complex that contain cysteine residues (NFS1 and 
ISCU2; Figure II-11 and Figure II-12). The effectiveness of acid in quenching sulfur transfer 
from NFS1 to ISCU2 was established by reactions under normal and quench conditions (Figure 
II-13). Initial studies with excess L-[35S]-cysteine substrate resulted in labeling of multiple 
cysteine residues on NFS1 and ISCU2 (Figure II-14). Some of these labeled cysteine residues, 
especially on NFS1 (C158, C163, C353, and C426), are likely due to side-reactions of the SDAecU 
complex that occur with excess cysteine substrate, long incubation times, and no additional 
reductant or iron; these conditions likely permit sulfur transfer reactions from persulfide species 
to excess cysteine and subsequent scrambling of the radiolabel.  
 The rates of persulfide formation on NFS1 and ISCU2 were determined using a 
stoichiometric amount of substrate. The SDAecU and SDAecUF complexes were combined with 
L-[35S]-cysteine, quenched after different reaction times, and the proteins were separated under 
quench conditions. Plotting the amount of radiolabel as a function of time revealed saturation 
between 0.20-0.25 labels per NFS1 (Figure II-15A and II-15B) and ISCU2 (Figure II-15C and 
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II-15D) for the SDAecU and SDAecUF complexes. Interestingly, the amount of label on NFS1 did 
not decrease at longer times as one might expect for sequential irreversible reactions using limited 
amounts of substrate ( Figure II-1, step 1 & 2). Persulfide formation on NFS1 and ISCU2, which 
were fit simultaneously, matched well with an equilibrium sulfur transfer model with a second 
cysteine turnover (Figure II-15E and II-16). Models that lack the equilibrium step (k-2) or second 
cysteine turnover (k3) did not adequately fit the data. The rates of persulfide formation on NFS1 
were constrained to be the same for the SDAecU (or SDAecUF) complex with or without a 
persulfide-bound ISCU2 (k1 = k3). Under these conditions, the slow step for both SDAecU and 
SDAecUF complexes was the formation of the persulfide species on NFS1 (Table II-1 and Figure 
II-15). FXN accelerated both the rate of persulfide formation on NFS1 (6.5 fold greater) and sulfur 
transfer from NFS1 to ISCU2 (30 fold greater). This kinetic model suggests the persulfide transfer 
reaction from NFS1 to ISCU2 is reversible with an equilibrium constant near one for both 
complexes. These experiments strongly support the proposed role of FXN as an allosteric activator 
that accelerates sulfur transfer chemistry 70, 77, 120. 
 
FXN affects the rate of persulfide cleavage by free cysteine.  Pulse-chase experiments were 
designed to evaluate the ability of FXN to labialize persulfide species and facilitate sulfur transfer 
chemistry. The cysteine desulfurase substrate, L-cysteine, was tested for its ability to cleave 
persulfide species associated with the SDAecU and SDAecUF complexes. A stoichiometric amount 
of L-[35S]-cysteine was first incubated with the individual complexes. The labeled complexes were 
then combined with non-radioactive L-cysteine for various times, quenched with acid, and 
analyzed as described above. For the SDAecU complex, spiking the sample with non-radioactive 
cysteine resulted in the loss of most of the labeled sulfur on both NFS1 and ISCU2, which occurred 
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at similar rates (Figure II-17A and II-17B; Table II-1). Intriguingly, the addition of FXN resulted 
in an approximate 5-fold increased rate of sulfur loss from NFS1, but almost no loss of label from 
ISCU2. To rationalize these results with the above equilibrium kinetic model (Figure II-15E), we 
suggest that cleavage of the [35S]-label occurs primarily from the mobile S-transfer loop of NFS1 
and not from ISCU2 (Figure II-17C). After NFS1 persulfide cleavage, slow cysteine turnover for 
the SDAecU complex results in re-equilibration of the label through interprotein sulfur transfer 
from ISCU2, explaining the similar persulfide depletion rates for NFS1 and ISCU2 (Table II-1 
and Figure II-17). In contrast, the SDAecUF complex is proposed to repopulate the mobile S-
transfer loop of NFS1 through rapid enzymatic cysteine turnover rather than re-equilibration, 
reconciling the apparent protection by FXN of the [35S]-label on ISCU2. Overall, these 
radiolabeling studies coupled to previous cysteine desulfurase assay results suggest that FXN 
accelerates PLP-associated chemistry and sulfur transfer reactions from NFS1 to thiol-containing 
molecules (ISCU2, DTT, and L-cysteine). 
 
FXN accelerates the decay of the PLP quinonoid intermediate for NFS1. To determine how 
FXN accelerates persulfide formation on NFS1, the PLP chemistry associated with the cysteine 
desulfurase reaction was directly probed using stopped-flow kinetics (Figure II-1, step 1). The 
proposed cysteine desulfurase mechanism includes sequential formation of cys-aldimine, cys-
quinonoid, and cys-ketimine intermediates (Figure II-18A) 125-127, which have distinct absorbance 
maxima. The SDAecU and SDAecUF complexes were combined with L-cysteine and changes in 
absorbance were monitored. A high substrate concentration (10 mM) was used to increase the 
accumulation of PLP-based intermediates in the reaction. The first observed event is a rapid 
increase in absorbance at 410 nm (Figure II-19), which was assigned to the cys-aldimine 
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intermediate 126. The SDAecUF sample developed this signal more rapidly (the formation occurred 
during the dead time of the instrument) compared to the SDAecU sample and accumulated 
approximately 8-fold more of this intermediate. Decay of this 410 nm species occurred at similar 
rates for the two complexes (Table II-2). The next intermediate, which absorbed maximally at 508 
nm and was assigned to the cys-quinonoid species 126, developed at similar rates in the presence 
and absence of FXN (Figure II-18B and Table II-1). Interestingly, the decay rate of this cys-
quinonoid intermediate was increased by a factor of four in the presence of FXN. Correspondingly, 
the formation of a species that absorbs at 340 nm (Figure II-19 S14B), which was assigned to the 
cys-ketimine intermediate 126, was also enhanced by the addition of FXN. We next found that 
addition of the bacterial homolog of FXN (CyaY) to the SDAecU complex also increased the decay 
rate (2.4 fold greater) of the cys-quinonoid intermediate (Figure II-18C and Table II-2), 
consistent with the ability of CyaY to activate the human cysteine desulfurase complex 76. Finally, 
ISCU2M106I was tested for its ability to mimic FXN and affect steps in the PLP chemistry of NFS1. 
Stopped-flow kinetics of the SDAecU
M106I complex showed slower development and slightly faster 
decay kinetics (1.2 fold greater) for the cys-quinonoid intermediate compared to the native SDAecU 
complex (Figure II-18D and Table 1). These stopped-flow experiments suggest that FXN, and to 
a smaller extent CyaY, affects the ability of NFS1 to accelerate the decay of the cys-quinonoid 
intermediate and generate the cys-ketimine species that is attacked by the mobile S-transfer loop 
during cysteine turnover. 
We then tested whether the mobile S-transfer loop influences the decay kinetics of the cys-
quinonoid intermediate in addition to its critical role in carbon-sulfur bond cleavage of the cys-
ketimine intermediate to generate the NFS1 persulfide species. The conversion of the quinonoid 
intermediate to the ketimine species requires protonation at the C4’ position (Figure II-18A). In 
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bacterial cysteine desulfurases, the mobile S-transfer loop cysteine is thought to be the proton 
donor for this step of the mechanism 126-127. We, therefore, generated the NFS1C381A variant to test 
if the mobile S-transfer loop cysteine of NFS1 functions as the general acid for quinonoid decay 
in the SDAec complex. Stopped-flow kinetics for the S
C381ADAecUF complex revealed that the 
quinonoid intermediate does not decay to generate the ketimine species (Figure II-18E), 
consistent with a proton donation role for C381. Overall, these results indicate FXN affects 
reactions associated with the NFS1 mobile S-transfer loop, which functions as a general acid, 
nucleophile, and sulfur transfer agent in Fe-S cluster biosynthesis.  
DISCUSSION 
 A direct link between the FXN gene and the neurodegenerative disease Friedreich’s ataxia 
(FRDA) was established in a seminal 1996 study 103. Typical FRDA patients have lower wild-type 
FXN expression levels (4-36% of controls) 128-132, suggesting a threshold level of FXN is required 
for normal function. FXN depletion results in the loss of activity for Fe-S cluster enzymes, 
increased iron accumulation in mitochondria, and enhanced sensitivity to oxidative stress 104. 
Strategies to treat FRDA have focused on iron chelators, antioxidants, and mechanisms to increase 
FXN levels 133-134. Unfortunately, FRDA remains incurable. An alternate approach to generating a 
FRDA treatment is to first determine the biological role of FXN in Fe-S cluster biosynthesis and 
then replace or bypass that function.  
An initial hypothesis was promoted that FXN functions as a chaperone that provides iron 
for Fe-S cluster assembly. This assignment was based on FXN depletion studies, which reveal a 
disruption of iron homeostasis and accumulation of iron in the mitochondria, and the lack of a 
designated iron chaperone for the Fe-S assembly pathway coupled to the presence of an iron-
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binding patch of carboxylate residues on FXN. However, FXN has weak iron binding affinity 
towards ferrous iron (55 µM), which is the substrate for Fe-S cluster biosynthesis, and the iron-
binding carboxylate patch residues are only semi-conserved 61-63, 112, 114-119.  Moreover, a similar 
iron overload phenotype is generated upon depletion of other members of the mitochondrial Fe-S 
assembly system 135, indicating that this phenotype is linked to loss of Fe-S clusters and not 
necessarily the ability to donate iron for this pathway. Furthermore, FRDA clinical variants for 
FXN have been identified on a region distinct from the carboxylate patch. These FRDA variants 
are not iron-binding residues and exhibit diminished ability to bind and activate the Fe-S assembly 
complex. Finally, the presence of ~150 µM labile iron pool in mitochondria could function as a 
feedstock for iron-containing proteins and raises the question as to whether a designated iron 
chaperone is even required for the Fe-S cluster biosynthetic pathway 136. Despite these concerns, 
many investigators still champion an iron donor role for FXN.  
More recently, much stronger evidence has been provided that supports a role for FXN in 
facilitating sulfur-based chemistry required for Fe-S cluster biosynthesis 31, 33, 70, 72, 77, 120, 123, 137-139. 
In this manuscript, we have extended these FXN functional studies to include stopped-flow 
interrogation of the eukaryotic cysteine desulfurase reaction and functional assays that incorporate 
both synthesis of the Fe-S cluster intermediate and transfer of the cluster to an acceptor protein. 
We provide a stepwise analysis of the role of FXN in (i) the PLP-associated formation of 
intermediates for the cysteine desulfurase NFS1; (ii) the kinetics of sulfur accumulation on NFS1; 
(iii) the kinetics of interprotein sulfur transfer to the scaffold protein ISCU2; (iv) the rate of Fe-S 
cluster intermediate formation on ISCU2; and (v) the kinetics of [2Fe-2S] cluster transfer from 
ISCU2 to the monothiol glutaredoxin GRX5 (Figure II-18A and Figure II-1).  
 29 
 
FXN accelerates steps associated with the mobile S-transfer loop of NFS1. Stopped-flow 
experiments revealed a clear role for FXN in accelerating the decay of the cys-quinonoid 
intermediate for the SDAecU complex (Figure II-18). The transformation of the cys-quinonoid 
intermediate to the cys-ketimine species requires protonation at the C4’ position. Substitution of 
the mobile S-transfer loop cysteine (C381A) of NFS1 compromised the ability to advance to the 
ketimine intermediate. This result is consistent with NFS1 residue C381 functioning as a general 
acid for this step in the mechanism, consistent with the prokaryotic cysteine desulfurases 126-127. 
Radiolabeling studies revealed that FXN also accelerates the rate of persulfide formation on NFS1, 
which results from attack of the deprotonated mobile S-transfer loop cysteine on the cys-ketimine 
intermediate, and the rate of interprotein sulfur delivery from the mobile S-transfer loop cysteine 
of NFS1 to ISCU2 (Figure II-15 and Table II-1). These enhanced rates of sulfur transfer also 
manifested in increased rates for the formation of [2Fe-2S] cluster intermediates on ISCU2 and in 
complete reactions in which [2Fe-2S] clusters were synthesized and transferred to GRX5.  
In addition, we determined how human ISCU2M106I, which is analogous to Isu1M107I 79, 121, 
is able to bypass the function of FXN and stimulate Fe-S cluster biosynthesis. ISCU2M106I was 
unable to replace FXN and affect the cysteine desulfurase kinetic parameters of the SDAec complex 
(Table II-1) and only had a minor stimulatory effect on the rate of Fe-S cluster formation on 
ISCU2. Consistent with this result, a recent crystal structure indicates that this ISCU2M106I 
substitution is unlikely to affect the mobile S-transfer loop of NFS1 140. Instead, we show that 
ISCU2M106I, unlike FXN, accelerates the rate of intact [2Fe-2S] cluster transfer from ISCU2 to 
GRX5 (Figure II-4C). Further analysis indicates that the ISCU2M106I substitution does not affect 
cluster stability on ISCU2 (Figure II-10) but appears to affect the [2Fe-2S] cluster binding 
equilibrium between ISCU2 and GRX5 (Figure II-4D). We hypothesize that substitutions on the 
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scaffold protein that are capable of bypassing FXN (including the substitution of Isu1 M107 with 
residues that have a higher hydropathy index such as valine or isoleucine) 79 favor hydrophobic 
protein-protein interactions that drive the cluster transfer reaction from ISCU2 to GRX5. 
Stimulation of different steps by FXN and ISCU2M106I is further supported by the additive effect 
that was observed in complete synthesis and transfer assays.  
 
Model for the role of FXN in Fe-S cluster biosynthesis. The eukaryotic SDAecU complex has 
an unusually low activity for a cysteine desulfurase enzyme (kcat < 10% of prokaryotic IscS) and 
requires FXN binding to stimulate activity and approach the catalytic turnover of IscS 33, 70. CyaY, 
which is the prokaryotic homolog of FXN, does not activate IscS and, instead, inhibits in vitro Fe-
S cluster biosynthesis 141. Swapping protein components between the prokaryotic and eukaryotic 
systems reveals that these activation/inhibition effects were surprisingly independent of the FXN 
and ISCU2 homologs, but dependent on the cysteine desulfurase 76. A recently determined 
structure of the SDAec complex revealed an incomplete substrate binding site with a solvent-
exposed PLP cofactor and an overall architecture in which ISD11 molecules mediate interactions 
between NFS1 subunits 33. Quaternary interactions between NFS1 subunits of the SDAec complex 
are quite different than its prokaryotic homologs IscS, which have contributions from each subunit 
to the active site channel of the other subunit 142-143. The Cory SDAec architecture provides a 
rationale for the essential nature of ISD11 in eukaryotes, the low basal levels of cysteine 
desulfurase activity for the SDAec or SDAecU complex, and the stimulation of sulfur-based 
chemistry upon FXN homolog binding to the eukaryotic cysteine desulfurases.  
In our model, the SDAecU is a low activity form of the Fe-S assembly complex with an 
incomplete substrate binding site and a mobile S-transfer loop that occupies a primarily non-
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productive conformation (Figure II-20). FXN functions as an allosteric activator and upon binding 
completes the substrate binding site and favors productive conformations for the mobile S-transfer 
loop cysteine. This alteration of the mobile S-transfer loop trajectory results in an acceleration of 
proton donation, which is necessary for advancing the cys-quinonoid intermediate, and an 
increased rate of persulfide formation on NFS1 and sulfur transfer to ISCU2. A role in binding and 
excluding non-productive conformations is further supported by the ability of the FXN homolog 
CyaY, which shares a mere 20% sequence identity with the human form, to impart the same effects 
on the cys-quinonoid decay (Figure II-18C) and on the cysteine desulfurase activity 76. Although 
the FXN-induced stimulation of the mobile S-transfer loop reactions is relatively small (Table II-
1; 3 to 30 fold), this may be sufficient to reach the modest in vivo activity threshold that supports 
Fe-S cluster biosynthesis and mitochondrial function. The incorporation of ISD11/ACP into the 
eukaryotic Fe-S cluster biosynthetic pathway is thereby a mechanism to integrate FXN as an 
activity control element or regulator that drives sulfur chemistry. Overall, these results provide 
new insights into FXN function and suggest strategies to replace (exclude non-productive mobile 
S-transfer loop conformations) or bypass FXN function (facilitate Fe-S cluster transfer from 
ISCU2) and provide potential new mechanisms to treat FRDA. 
 
MATERIALS AND METHODS 
Protein Preparations. Plasmids containing human NFS1 (Δ1-55) and ISD11 (pZM4) were 
generously provided by S. Leimkuhler 144. The NFS1 and ISD11 plasmids were transformed into 
E. coli strain BL21(DE3) cells and copurified with the bacterial ACP (ACPec) as the SDAec 
complex 33. Human ISCU2 (Δ1-35) and FXN (Δ1-55) were separately expressed and purified as 
previously described 70. The spontaneous conversion of Δ1-55 FXN to the truncated form was 
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confirmed by SDS-PAGE 70. The QuikChange protocol (Agilent) was used to introduce the M106I 
point mutation into the ISCU2-pET11a plasmid 70 and the C381A point mutation into the NFS1-
pET15b plasmid 144. The protein sequence numbering for the M106I variant does not include the 
ISCU2 signal sequence to be consistent with the literature for the bacterial and yeast homologs. 
The MEGAWHOP 145 method was used to substitute human GRX5 for FDX in the pHis-GFP-
TEV-FDX plasmid 146 and produce pHis-GFP-TEV-GRX5. Sequences were confirmed by the Gene 
Technologies Lab (Texas A&M University). 
The pHis-GFP-TEV-GRX5 plasmid was transformed into Rosetta (DE3) cells (VWR). The 
cells were grown in LB media (VWR) at 37 °C until the OD600 reached 0.5 and then β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM. The temperature was 
decreased to 16 °C and the cells were grown for an additional ~16 h. The harvested cell pellets 
were resuspended in Buffer A (50 mM Tris and 250 mM NaCl at pH 7.5) with 5 mM imidazole 
and lysed by sonication (Branson sonifier 450). The soluble fraction was loaded on a Ni-NTA 
column (5 mL; GE Life Sciences) and the his-GFP-TEV-GRX5 fusion was eluted using Buffer A 
and a linear gradient between 5 and 500 mM imidazole. The green fractions were combined and 
dialyzed into Buffer B (50 mM Tris, pH 7.5). The sample was then incubated overnight at room 
temperature with TEV protease (1:50 molar ratio of protease to fusion protein). The cleaved 
material was then loaded onto an anion exchange column (27 mL; 16 mm × 13.5 cm, POROS HQ 
50) and eluted with Buffer B and a linear gradient from 0 to 1 M NaCl. The GRX5 fractions were 
concentrated and loaded onto a 26/60 Sephadex 100 column (GE Life Sciences) equilibrated with 
50 mM HEPES and 150 mM NaCl at pH 7.5. Monomeric fractions with > 96% purity were 
concentrated, frozen in liquid nitrogen and stored at −80 °C. Unless otherwise stated, all protein 
manipulations and reactions were carried out in an anaerobic glove box (MBRAUN; maintained 
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at ~14 °C with O2 < 1 ppm). Protein concentrations were estimated using the following extinction 
coefficients: SDAec using 10.9 mM
-1cm-1 at 420 nm, ISCU2 using 8490 M-1cm-1 at 280 nm, FXN 
using 26030 M-1cm-1 at 280 nm, and GRX5 using 17780 M-1cm-1 at 280 nm 70, 147. Protein variants 
were assumed to have the same extinction coefficient as the native proteins.  
 
Complete Fe-S cluster synthesis and transfer reactions. The complete reaction assays included 
0.5 µM SDAec, 20 µM ISCU2 (or ISCU2
M106I), 20 µM (or 0 µM) FXN, 40 µM GRX5, and 400 
µM Fe(NH4)2(SO4)2 and Buffer C (50 mM HEPES, 150 mM KCl and 10 mM MgCl2 at pH 7.5). 
The reactions were initiated by the addition of 100 µM L-cysteine and 10 mM GSH. Cluster 
formation on GRX5 was then measured for SDAecU, SDAecUF, SDAecU
M106I and SDAecU
M106IF 
by monitoring the ellipticity change at 450 nm using a Chirascan circular dichroism (CD) 
spectrometer (Applied Photophysics). Cuvettes (1 cm path length) were sealed with a rubber 
septum and electrical tape in a glove box. The kinetic data were fit to an exponential rise equation 
([y=y0+A0*(1 - exp(-k*t))] where the k is the apparent rate of cluster formation on GRX5) using 
Kaleidagraph (Synergy Software, Reading, PA).  
 
Fe-S cluster assembly reactions on ISCU2. Fe-S assembly reactions on ISCU2 contained 10 µM 
SDAec, 30 µM ISCU2 (or ISCU2
M106I), 30 µM FXN (when added), 400 µM Fe(NH4)2(SO4)2 and 
Buffer C. The reactions were initiated with 1 mM L-cysteine. The formation of [2Fe-2S] clusters 
was monitored by the change in ellipticity at 330 nm 123. The initial increase in ellipticity was 
plotted with time and fit a linear equation (R2 values ≥ 0.97) using Kaleidagraph.  
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Cysteine desulfurase activity measurements. Cysteine desulfurase activities were measured for 
each complex using a slightly modified methylene blue assay 70, 148. Protein complexes were 
generated with final concentrations of 0.5 µM SDAec, 1.5 µM ISCU2 (or ISCU2
M106I), and 1.5 µM 
FXN (when included). The complexes were combined with 4 mM D,L-DTT and incubated for 15 
min anaerobically on a heating block at 37 °C. Different concentrations of L-cysteine were added, 
incubated for 6 min, and quenched with 20 mM N,N'-diphenyl-p-phenylenediamine (DPD) (in 7.2 
M HCl) and 30 mM FeCl3 (in 1.2 M HCl). After 20 min, the samples were centrifuged and the 
absorbance was measured at 670 nm. The amount of sulfide produced was determined for each 
data point using a standard curve. Rates ([S2-]/([NFS1]*min)) were plotted against the amount of 
L-cysteine added and fit to the Michaelis-Menten equation using Kaleidagraph. 
 
[2Fe-2S] cluster transfer reactions from enzymatic and chemically reconstituted ISCU2 to 
GRX5. Clusters were enzymatically generated on ISCU2 (or ISCU2M106I) using 0.5 µM SDAec, 
20 µM ISCU2 (or ISCU2M106I), and 400 µM Fe(NH4)2(SO4)2 and Buffer C. The reactions were 
initiated with of 100 µM L-cysteine and 10 mM GSH. After 160 min, the enzymatic formation of 
[2Fe-2S] clusters appeared to be completely based on the lack of changes in ellipticity at 450 nm. 
A solution containing 40 µM GRX5 (with or without 20 µM FXN) was then injected with an air-
tight syringe into the sealed cuvette to initiate the transfer reactions. The change in ellipticity was 
plotted with time and fit a linear equation with Kaleidagraph (R2 values ≥ 0.97). 
 [2Fe-2S] clusters were chemically generated on ISCU2 (or ISCU2M106I) by reacting 30 
µM of apoprotein with 600 µM ferric ammonium citrate, 600 µM Na2S and 10 mM D,L-DTT for 
an hour. DTT and the excess iron and sulfide were then removed with a desalting column (5 mL, 
GE Healthcare) equilibrated in Buffer C. Iron was quantitated with the ferrozine assay (extinction 
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coefficient of 28,000 M−1cm−1 at 562 nm) 149 and sulfide was quantitated using a methylene blue 
assay with an additional pre-treatment of the protein with NaOH and zinc acetate to release bound 
sulfide 150. The protein concentration was determined using the Bradford assay. Chemically 
reconstituted ISCU2 had 2.1 ± 0.3 iron and 2.0 ± 0.6 sulfide atoms per protein, whereas ISCU2M106I 
had 1.9 ± 0.5 iron and 2.2 ± 0.1 sulfide atoms per protein. Cluster transfer reactions were initiated 
by combining [2Fe-2S]-ISCU2 or [2Fe-2S]-ISCU2M106I with 60 µM GRX5 and 10 mM GSH. 
Transfer reactions were monitored by the change in ellipticity at 450 nm.  
 
[2Fe-2S] cluster extrusion assay. [2Fe-2S] clusters were assembled on 30 µM ISCU2 (or 
ISCU2M106I) in the presence of 10 µM SDAec, 100 µM L-cysteine, 400 µM Fe(NH4)2(SO4)2 and 
10 mM GSH. 4 mM D,L-DTT was added to the samples to initiate the cluster extrusion reaction, 
which was followed by the loss of ellipticity at 330 nm. The extrusion rates were determined by 
fits to a linear equation. 
 
Protein separation and 35S quantification for sulfur transfer reactions. L-[35S]-cysteine 
(PerkinElmer, 10.2  µM, 1.00796 mCi) was diluted 50 times by non-radioactive L-cysteine to 
generate a 1 mM stock solution (final concentration of L-[35S]-cysteine was 204 nM). Proteins 
from Fe-S assembly complexes (SDAec and ISCU2) were applied to a reverse phase C4 column 
(Waters) attached to a HPLC (1260 Infinity, Agilent Technologies) and separated using a gradient 
from either 0 to 100% or from 30% to 70% Buffer D (0.1 % TFA in water, pH 2.0) with the 
remainder of the composition made up of Buffer E (60% CH3CN, 40% isopropanol, 0.1% TFA). 
Both the absorbance (diode array detector) and, after mixing with scintillation cocktail (BioCount 
111182), the [35S] signal (Model 5C β-RAM radio-HPLC detector, LabLogic) were recorded for 
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the eluted proteins. The retention time of NFS1 (ISD11 and ACPec do not contain cysteine residues 
required for persulfide formation) was determined by reacting a 25 µL aliquot of the SDAec 
complex (37.5 µM) with 25 µL of L-[35S]-cysteine (final concentration of 500 µM) for 30 min. 
The reaction was stopped by addition of 50 µL quenching solution and the proteins were separated 
under quench conditions. The quenching solution was made by mixing 1 volume of concentrated 
HCl with 4 volumes of 6 M guanidine hydrochloride (pH < 1). The retention time for ISCU2 was 
determined using absorbance or reaction of the SDAecU complex with L-[
35S]-cysteine and 
comparison to the SDAec complex. Note that FXN, like ISD11 and ACPec, lacks cysteine residues 
needed to form a persulfide intermediate. To demonstrate that the quench solution inhibits sulfur 
transfer, labeled NFS1 was first generated by reacting the SDAec complex (30 µM) with L-[
35S]-
cysteine (400 µM final concentration, 45 µl total reaction volume) for 30 min. The labeled NFS1 
was either (i) incubated with ISCU2 (80 µM, 5 µL) for 30 min, followed by the addition of 50 µL 
quenching solution; or (ii) first combined with 50 µL quenching solution and then incubated with 
ISCU2 (80 µM, 5 µL) for 30 min. Samples were analyzed by a reverse phase chromatography 
under quench conditions. NFS1Data collection and analysis were performed with Laura software 
(LabLogic). To quantitate the amount of persulfide associated with the peak, the area under the 
scintillation curve (in CPM) was converted into a [35S] concentration using a standard curve 
generated from known amounts of L-[35S]-cysteine and then multiplied by the dilution factor 
(unlabeled / labeled L-cysteine = 4901.96). 
 
Assays for monitoring persulfide formation and decay. For the persulfide formation and decay 
assays, 30 M SDAec and 30 M ISCU2 were combined to generate the SDAecU complex, which 
was converted to the SDAecUF complex by the addition of 75 M FXN. The SDAecU and 
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SDAecUF complexes were reacted with either 30, 200, or 600 M cysteine (0.0204% [35S]-
cysteine), incubated at 37°C for different lengths of time (30 sec to 1 h), and diluted 4-fold into 
the quenching solution described above. The amount of persulfide associated with NFS1 and 
ISCU2 was calculated as described above, plotted against time, and fit to a reaction scheme (see 
below) using KinTek software (KinTex Corporation, Austin, TX). To determine which cysteine 
residues were labeled with persulfide species, the SDAecU complex was combined with 300 µM 
L-cysteine, incubated at 37 °C for 30 min, and quenched with concentrated HCl. The sample was 
digested with pepsin (100:1 sample:pepsin based on concentration in mg/mL) at 22 °C for 30 min 
and subjected to LC/MS/MS analysis (Center for Mass Spectrometry (CMS) at Texas A&M 
University). 
Pulse-chase experiments were conducted by first reacting the SDAecU and SDAecUF 
complexes (30 M SDAec, 30 M ISCU2, with or without 75 M FXN) with 30 M [35S]-cysteine 
for 40 min (the amount of label maximized after 10-20 min) to generate radiolabeled NFS1 and 
ISCU2. Next, we added a final concentration of 1 mM non-radioactive L-cysteine to the samples 
and then diluted 4-fold into the quenching solution at various times. The number of residual 
persulfide labels on NFS1 and ISCU2 were determined and fit to an exponential decay equation 
[y=y0+A0*exp (-k*x)] using Kaleidagraph, where the k value gives the apparent rate of persulfide 
loss.  
 
Validation of data fitting for persulfide formation kinetics. The data were fitted to a simulated 
mechanism according to the reaction scheme (Fig. 2E) using KinTek software. The estimation of 
error was determined by FitSpace confidence contour analysis. FitSpace determines the goodness 
of the fit by measuring the dependence of the sum of square errors (SSE) on each pair of parameters 
 38 
 
while all other parameters were varied. The confidence interval of all the fitted parameters was 
constrained by χ2 threshold values of 0.99 and 0.997 for the SDAecU and SDAecUF data, 
respectively. These thresholds indicate that varying the parameter within the confidence interval 
would not increase the χ2 value more than 1% (SDAecU) and 0.3% (SDAecUF) from the minimum 
χ2 (χ2min) value, which represents the best fit. Confidence contour plots are provided that indicate 
well-defined regions determined by χ2 threshold values (red colored patches). 
 
Stopped-flow kinetics for cysteine desulfurase reaction. 100 µM SDAecU (100 µM SDAec + 
100 µM ISCU2) or 100 µM SDAecUF (100 µM SDAec + 100 µM ISCU2 + 100 µM FXN) in assay 
buffer (50 mM HEPES, 250 mM NaCl, pH 7.5) was placed in one of the syringes of the stopped-
flow apparatus (KinTek Corporation). The other syringe contained 10 mM L-cysteine. The 
samples were mixed by simultaneously pressing both syringes. Formation of the aldimine, 
quinonoid, and ketimine intermediates were followed by monitoring changes in absorbance at 410, 
508 and 340 nm, respectively. For the aldimine and quinonoid kinetics, traces monitored at 410 
nm and 508 nm with time were fitted with Origin software (OriginLab) to a consecutive B equation 
[y = y0 + (k1*[A]0/(k2-k1))*(exp(-k1*t)-exp(-k2*t))], where k1 and k2 are rate constants of the 
formation and decay of intermediates respectively. The ketimine kinetics could not be adequately 
fit using a consecutive B equation. 
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Figure II-1. Steps of iron sulfur cluster biosynthesis in eukaryotes. 
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Figure II-2. Visible CD spectra for holo-ISCU2 and holo-GRX5 
have distinct features. CD spectra were recorded for 25 µM [2Fe-
2S]-ISCU2 (red) and 30 µM [2Fe-2S]-GRX5 (blue). 
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Figure II-3. Final CD spectra for complete Fe-S assembly and 
transfer reactions resemble [2Fe-2S]-GRX5. [2Fe-2S] cluster 
synthesis and transfer reactions to GRX5 for the SDAecU (red), 
SDAecUF (blue), SDAecUM106I (green) and SDAecUM106IF (black) 
complexes. Spectra are shown before the reaction is initiated (fine 
lines) and at end points of assay (bold lines; see Figure II-4A).  
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Figure II-4. FXN and the ISCU2M106I substitution accelerate different steps in Fe-S cluster 
biosynthesis. A) Kinetics of Fe-S cluster synthesis and transfer to GRX5 were monitored for different 
assembly complexes by the change in ellipticity at 450 nm. The average change in ellipticity (n = 3; 
maximum error of 1.8 in ellipticity) is plotted and fit with an exponential rise equation. The final CD spectra 
are shown in Figure II-3. B) Fe-S cluster assembly reactions on ISCU2 were monitored for assembly 
complexes by the change in ellipticity at 330 nm. The average change in ellipticity (n = 3; maximum error 
of 1.8 in ellipticity) is plotted and fit with a linear equation. The complete time course of the reactions and 
final CD spectra are shown in Figure II-5. C) Kinetics of cluster transfer from pre-formed holo-ISCU2 to 
apo-GRX5 were monitoring by the change in ellipticity at 450 nm. Reactions were initiated (time = 0) by 
the anaerobic injection of GRX5 (with or without FXN). The average change in ellipticity (n = 3; maximum 
error of 0.8 in ellipticity) is plotted and fit with a linear equation. The CD spectra before addition of GRX5 
and the complete time course of the reaction are shown in Figure II-6 and II-7. D) Chemically reconstituted 
ISCU2 (or ISCU2M106I) was reacted with GRX5 and the [2Fe-2S] cluster transfer was monitored by the 
increase in ellipticity at 450 nm. Full spectra are shown in Figure II-9. Color scheme: SDAecU (red), 
SDAecUF (blue), SDAecUM106I (black) and SDAecUM106IF (green). 
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Figure II-5. Full time course and final CD spectra for Fe-S cluster synthesis reactions on ISCU2. A) 
Fe-S assembly intermediate formation on ISCU2 were monitored by the change in ellipticity at 330 nm and 
shown for different assembly complexes.  B) The overall similarity in the final CD spectra (after 60 min) for 
the different complexes indicates the formation of analogous Fe-S clusters. The complexes are indicated 
by their color in the figure: SDAecU (red), SDAecUF (blue), SDAecUM106I (black) and SDAecUM106IF (green). 
 
 
 
 
 
 
 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-6. Fe-S assembly complexes containing native ISCU2 or ISCU2M106I exhibit similar kinetic 
parameters for the cysteine desulfurase reaction. Cysteine desulfurase activities for complexes A) without 
(SDAecU in red and SDAecUM106I in black) and B) with FXN (SDAecUF in blue and SDAecUM106IF in green) at 
different concentrations of L-cysteine. Lines through the data are the fits to the Michaelis-Menten equation. 
Experiments were performed in triplicate. 
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Figure II-7. CD spectra of Fe-S cluster bound species in transfer reaction from ISCU2 to GRX5. Fe-S 
clusters were synthesized in situ on ISCU2 (or ISCU2M106I) for A) SDAecU (red), B) SDAecUF (blue) and C) 
SDAecUM106I (black) complexes. CD spectra are recorded (dotted lines) after 160 min from initiation of the 
reaction. The samples were then spiked with 40 µM GRX5 (with or without 20 µM FXN) and the CD spectra was 
recorded 20 min later (solid line) later. Kinetic traces monitored at 450 nm are shown in Figure II-8. 
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 Figure II-8. Incorporation of the ISCU2M106I substitution 
increases the cluster transfer rate from ISCU2 to GRX5. Fe-S 
clusters were synthesized on ISCU2 in reactions described in 
Figure II-7. The ellipticity at 450 nm was monitored for the SDAecU 
(red), SDAecUF (blue) and SDAecUM106I (black) complexes. Samples 
were spiked with GRX5 (with or without FXN) 160 min after the 
reaction was initiated. Experiments were performed in triplicate. 
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Figure II-9. Cluster transfer from chemically reconstituted 
ISCU2 and ISCU2M106I to GRX5. 30 µM [2Fe-2S] cluster bound 
ISCU2 (black) or ISCU2M106I (grey) before (dashed line) and 
after (solid line) reaction with 60 µM GRX5 in the presence of 10 
mM GSH.  
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Figure II-10. [2Fe-2S] clusters bound to ISCU2 and ISCU2M106I have comparable stabilities. A) [2Fe-2S] 
clusters were enzymatically assembled on ISCU2 (red) or ISCU2M106I (blue).  The addition of DTT initiated the 
cluster extrusion reaction, which was followed by the loss of ellipticity at 330 nm. The extrusion rates (0.22 
mdeg/min for ISCU2 and 0.19 mdeg/min for ISCU2M106I) were determined by fits to a linear equation. 
Experiments were performed in duplicate. B) Complete CD spectra are shown for the ISCU2 (red) and 
ISCU2M106I (blue) before (solid line) and 30 min after (dashed line) the addition of DTT.  
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Figure II-11. Separation of subunits for the SDAecU complex. 
Assembly complex subunits were separated on a reverse phase 
column (gradient composed of CH3CN, isopropanol and TFA; see 
Methods). ISCU2 (140 µM, red) eluted with a retention time of ~6 
min. The SDAec sample (45 µM, blue) had two peaks with retention 
times of ~6 min and ~12 min. The SDAecU sample (45 µM SDAec 
plus 140 µM ISCU2, green) had increased peak intensity with a 
retention time at ~6 min, consistent with the presence of ISCU2.  
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Figure II-12. Separation and detection of [35S]-labeled NFS1. The SDAec 
complex was reacted with L-[35S]-cysteine, quenched with acid, and the proteins 
were separated on a reverse phase column under quench conditions. The 
retention time for NFS1 (~11 min) was identified by the radioactivity peak 
(bottom panel). The band at ~6 min in the top panel was assigned to ISD11 
and/or ACPec.  
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Figure II-13. Evidence that acid quenching inhibits interprotein sulfur transfer. NFS1 was labeled by 
combining the SDAec complex with L-[35S]-cysteine for 30 min. A) The labeled NFS1 was incubated with 
ISCU2 for 30 min, followed by the addition of the quenching solution. The [35S] label was associated with both 
the NFS1 (peak at ~12 min) and ISCU2 (peak at ~7 min). B) The labeled NFS1 was first combined with 
quenching solution and then incubated with ISCU2 for 30 min. The [35S] label was associated with NFS1 
(peak at ~12 min) but not ISCU2 (peak at ~7 min). Samples were analyzed by a reverse phase 
chromatography similar to Figure II-11 and II-12. Note that the peaks for ISD11/ACPec coincides with ISCU2 
but have no cysteine residues that could form a persulfide species. 
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Figure II-14. Reactions with excess cysteine result in multiple persulfide species on NFS1 and 
ISCU2. The SDAecU complex (30 µM SDAec and 30 µM ISCU2) was reacted with 200 or 600 µM L-
[35S]-cysteine at 37 °C and quenched at various times. The protein subunits were separated by reverse 
phase chromatography and the amount of radioactivity was quantitated for A) NFS1 and B) ISCU2.  
 
 53 
 
 
 
 
 
 
Figure II-15. FXN accelerates the persulfide formation kinetics on both NFS1 and ISCU2. SDAecU and 
SDAecUF complexes were reacted with a stoichiometric amount of L-[35S]-cysteine, quenched with acid, and 
the proteins were separated using conditions similar to Figure II-11. Formation of [35S]-persulfide was 
quantitated and plotted for A) NFS1 (SDAecU), B) NFS1 (SDAecUF), C) ISCU2 (SDAecU), and D) ISCU2 
(SDAecUF). E) Best-fit kinetic model (k1 = k3) for persulfide accumulation on cysteine residues of NFS1 and 
ISCU2. The data for SDAecU or SDAecUF were fit simultaneously with KinTek and the fits were validated using 
FitSpace (Figure II-16). Blue, green, and red dashed lines represent the simulated amounts of persulfide on 
NFS1, ISCU2, or both NFS1 and ISCU2, respectively. Black lines indicate the total amount of simulated 
persulfide on NFS1 or ISCU2.  
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Figure II-16. Analysis of goodness of fit for persulfide formation model by FitSpace.  Calculation of the 
(χ2min/ χ2) when k1, k2 and k-2 were varied individually for the A) SDAecU and B) SDAecUF complexes. For the 
best fit parameter value, (χ2min/ χ2) approaches one. Deviation from the best fit parameter value increase χ2 for 
the fit and, in turn, decreases the (χ2min/ χ2) value. Heatmap describing 2D confidence contour (see Materials 
and Methods) for the C) SDAecU and D) SDAecUF complexes indicate that all the parameters are well 
constrained. 
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Figure II-17. FXN accelerates the persulfide decay kinetics from NFS1. SDAecU (red) and SDAecUF (blue) 
complexes were reacted with stoichiometric amounts (30 M) L-[35S]-cysteine for 40 min and then chased with 
1 mM non-radioactive L-cysteine. Samples were then quenched with acid at various times and the amount of 
remaining [35S]-label on A) NFS1 and B) ISCU2 were determined. The data were fit to an exponential decay 
or linear (loss of ISCU2 label from SDAecUF complex) equation. C) Model for the effect of FXN on persulfide 
decay from the SDAecU and SDAecUF complexes. The NFS1 persulfide is proposed to be the primary species 
cleaved during the chase experiment. In the presence of FXN, the persulfide on NFS1 is rapidly regenerated 
by turnover with non-radioactive L-cysteine. In the absence of FXN, slower cysteine desulfurase turnover 
results in re-equilibration (transfer) of the ISCU2 radiolabeled sulfur (atom colored red) to NFS1 and 
subsequent cleavage.  
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Figure II-18. FXN accelerates the decay of the quinonoid intermediate. A) Scheme showing steps of PLP 
chemistry that leads to C-S bond cleavage and persulfide formation on the mobile loop cysteine (NFS1-SSH). 
Stopped-flow kinetics for the cis-quinonoid decay of B) SDAecU and SDAecUF complexes, C) SDAecU and 
SDAecUCec (includes E. coli FXN homolog CyaY), D) SDAecU and SDAecUM106I and E) SDAecUF and 
SC381ADAecUF. The traces are an average of three independent experiments. The rates for the development 
and decay of the quinonoid intermediate were obtained by nonlinear regression analysis (solid lines). 
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Figure II-19. Effect of FXN on the cys-aldimine and cys-ketimine formation and decay kinetics. The 
SDAecU (red) and SDAecUF (blue) complexes were reacted with 10 mM L-cysteine and the absorbance at A) 
410 nm (assigned to the cys-aldimine intermediate) and B) 340 nm (assigned to the cys-ketimine intermediate) 
were recorded as a function of time in a stopped-flow experiment. The lines through the data in A) is a fit to a 
consecutive B equation (see Methods). The data in B) could not be meaningfully fit a rate equation.  
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Figure II-20. Model for how FXN and the FXN bypass variant accelerate Fe-S cluster biosynthesis. A) 
Cysteine binding to NFS1 generates the Cys-quinonoid intermediate. B) In the absence of FXN, the NFS1 
mobile S-transfer loop exists primarily in a non-productive conformation. FXN binding favors the active 
conformation. C) The FXN promoted conformation of the S-transfer loop allows its cysteine to function as a 
general acid and accelerate the decay of the cys-quinonoid intermediate. D) The deprotonated cysteine of the 
S-transfer loop nucleophilically attacks the cys-ketimine intermediate to generate a persulfide intermediate on 
NFS1 (NFS1-SSH). E) FXN favors the appropriate trajectory to deliver sulfur and produce a persulfide species 
on ISCU2 (ISCU2-SSH). F) A second cysteine turnover generates the NFS1-SSH ISCU2-SSH intermediate. 
G) Incorporation of ferrous iron and electrons generates the [2Fe-2S] intermediate on ISCU2. H) The [2Fe-
2S] cluster is transferred to the apo acceptor GRX5. Steps labels in red are accelerated by FXN.  Steps 
labeled in blue are accelerated by the ISCU2M106I bypass variant.  
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Table II-1. Kinetic data for Fe-S assembly complexes (human). 
 
      
Relative Rate with respect to 
SDAecU 
  SDAecU SDAecUM106I SDAecUF SDAecUM106IF SDAecUM106I SDAecUF 
Cysteine 
desulfurase 
activity 
kcat (min
-1) 0.82 ± 0.03a 0.90 ± 0.02 10.07 ± 0.15a 7.34 ± 0.34 1.1 12.3 
KM (µM) 0.62 ± 0.11
a 0.65 ± 0.09 11.61 ± 0.92a 8.0 ± 2.0   
Complete 
reaction 
Cluster synthesis 
& transfer to 
GRX5 (mdeg/min 
X10-3) 
4.1 ± 0.3 11.3 ± 0.2 14.4 ± 0.2 27.2 ± 0.9 2.8 3.5 
Cluster 
transfer 
Cluster transfer 
ISCU2 to GRX5 
(mdeg/min X 10-3) 
70 ± 0.5 130 ± 1 68 ± 5 ND 1.9 1.0 
Cluster 
synthesis 
Cluster formation 
on ISCU2 
(mdeg/min X 10-2) 
24 ± 1  37 ± 2 68 ± 2 55 ± 1 1.5 2.8  
Sulfur 
transfer 
reactions 
with [35S]-
Cys 
(min-1 X 10-2) 
 
Persulfide 
formation on NFS1 
(k1 and k3) 
0.8  
(0.75 – 0.81)b 
ND 
5.2 
(5.1 – 5.2)b 
ND ̶ 6.5 
Persulfide transfer 
NFS1 to ISCU2 
(k2) 
8.6 
(8.5 – 9.6)b 
ND 
266 
(252 – 282)b 
ND ̶ 30.9  
Persulfide back 
transfer ISCU2 to 
NFS1 (k-2) 
8.4 
(8.2 –10.0)b 
ND 
254 
(241 – 270)b 
ND ̶ 30.2  
Pulse-chase 
experiments 
(min-1 X 10-2) 
Persulfide decay 
for NFS1 
8 ± 1c ND 42 ± 7c ND ̶ 5.3 
Persulfide decay 
for ISCU2 
6 ± 2c ND 
0.048 ± 
0.0015c,d 
ND ̶ 0.008 
PLP 
Chemistry 
Cys-quinoid 
formation (s-1) 
19.5 ± 0.5 9.3 ± 0.1 17.5 ± 0.4 ND 0.5 0.9 
Cys-quinoid decay 
(s-1) 
1.19 ± 0.03 1.47 ± 0.01 4.80 ± 0.07 ND 1.2 4.0 
aData from reference 4, bThe values in parentheses denotes the lower and upper limit of the best fit value (rate constant). These were calculated 
at 99% and 99.7% confidence contours for SDAecU and SDAecUF complexes, respectively. 
cSpiked with 1 mM non-radioactive L-cysteine. 
dDetermined with linear fit. ND – Not determined. 
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Table II-2. Rates for individual steps in the cysteine desulfurase reaction for Fe-S assembly complexes. 
 
Rate of Cys-
aldimine Formation 
(mAU.s-1) 
Rate of Cys-
aldimine Decay 
(mAU.s-1) 
Rate of Cys-
quinonoid Formation 
(mAU.s-1) 
Rate of Cys-
quinonoid 
Decay 
(mAU.s-1) 
Relative rate of 
cys-quinonoid 
decay 
SDAecU 96 ± 15 1.82 ± 0.05 19.5 ± 0.5 1.19 ± 0.03 1 
SDAecUM106I ̶ ̶ 9.3 ± 0.1 1.47 ± 0.01 1.2 
SDAecUF ̶ 1.70 ± 0.01 17.5 ± 0.4 4.80 ± 0.07 4.0 
SDAecUCec ̶ ̶ 5.6 ± 0.2 2.9 ± 0.1 2.4 
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CHAPTER III                                                                                                                          
CYAY INHIBITS IRON SULFUR CLUSTER BIOSYNTHESIS IN PROKARYOTES BY 
INHIBITING SULFUR TRANSFER FROM ISCS TO ISCU 
 
INTRODUCTION 
 
Iron sulfur clusters are essential protein cofactors for most living organisms in all three 
domains of life93. They play crucial roles in electron transport, catalysis, regulation of gene 
expression, iron homeostasis etc151-152. Hence, iron sulfur cluster biosynthesis needs to be very 
tightly regulated. In prokaryotes, three iron sulfur cluster biosynthesis pathways are known – 1) 
Nitrogen fixation (NIF)3-4, 2) Iron sulfur cluster assembly (ISC)7-9 and 3) Sulfur Formation 
pathway (SUF)153. Among these, ISC pathway is the housekeeping pathway and operates under 
‘normal’ growth conditions. On the other hand, NIF and SUF are more specialized systems. NIF 
is used exclusively to synthesize iron sulfur clusters on nitrogenases whereas SUF is used to make 
iron sulfur cluster under oxidative stress and limited iron conditions154. ISC pathway is also the 
only pathway that is shared between prokaryotes and eukaryotes. Therefore, the proteins involved 
in ISC pathway are highly conserved. In E. coli, ISC operon encodes genes for IscR (iron sulfur 
cluster containing transcriptional regulator), IscS (cysteine desulfurase)10, IscU (scaffold 
protein)89, 92, IscA (alternate scaffold/iron donor)11, 155-156, HscB (co-chaperone)17-18, HscA 
(chaperone)18, 157, Fdx (putative electron donor)86, 158 and IscX (effector)159-160. 
The mechanism of iron sulfur cluster biosynthesis is also very well conserved across 
prokaryotes and eukaryotes. IscU is the scaffold protein on which the cluster is assembled. IscS is 
a PLP dependent cysteine desulfurase that provides the sulfur to scaffold protein IscU in the form 
of a persulfide via an absolutely conserved mobile loop cysteine assisted conversion of cysteine to 
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alanine. That sulfane sulfur then reacts with ferrous iron and electrons provided most likely from 
reduced Fdx to form a [2Fe2S]2+ on IscU in a process that is still very poorly understood. The 
scaffold protein then transfers the cluster to Grx4 in a reaction accelerated by HscA-HscB pair in 
an ATP dependent manner. Grx4 then transfers the clusters downstream to terminal acceptors like 
Fdx, Rieske etc. 
Frataxin (FXN), a eukaryotic protein, has been shown to act as an allosteric activator of 
the eukaryotic cysteine desulfurase70. It activates iron sulfur cluster biosynthesis in eukaryotes by 
accelerating cys-aldimine formation, cys-quinonoid decay, persulfide formation on cysteine 
desulfurase NFS1 and sulfur transfer from NFS1 to scaffold protein (ISCU2) (CHAPTER II). 
Absence of this activation in absence of FXN such as in neurodegenerative disease Friedreich’s 
Ataxia (FRDA)38, 40 leads to impairment of iron sulfur cluster biosynthesis, severe iron overload 
in mitochondria and subsequent elevated oxidative stress that cause severe damage to the cell 
leading to cell death39, 57, 161. In stark contrast to eukaryotic system, CyaY (bacterial homolog of 
FXN) has been shown to inhibit iron sulfur cluster assembly on scaffold protein in vitro75. It was 
later shown that FXN also inhibits iron sulfur cluster biosynthesis on E. coli IscU and that the 
inhibitory effect of CyaY/FXN is dependent on cysteine desulfurase (prokaryotic vs. eukaryotic)76. 
However, the exact mechanism of how CyaY inhibits iron sulfur cluster biosynthesis on IscU is 
still unknown. Deletion of CyaY did not produce any of the phenotypes associated with FXN 
deletion most likely because under normal growth conditions, iron sulfur cluster biosynthesis is 
not required to be slowed down/inhibited162. However, it was recently shown that CyaY is required 
for cellular fitness under oxidative stress and limited iron conditions and has an overall positive 
role160, 163-164. Along the same line, a single mutation (I108M) on IscU was shown to make the cell 
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dependent on CyaY by somehow slowing down iron sulfur cluster biosynthesis creating condition 
of oxidative stress165. 
In this study, we aimed to determine how CyaY inhibits iron sulfur cluster biosynthesis on 
IscU and whether the inhibition translates to a slower rate of cluster delivery to terminal targets. 
We also investigated in detail the effect of I108M mutation on E. coli IscU on the rate of cluster 
assembly on IscU in presence and absence of CyaY. Using a combination of stopped-flow 
experiments, a novel persulfide formation assay and CD spectroscopy, we determined that CyaY 
slows down iron sulfur cluster formation on IscU by inhibiting sulfur transfer from IscS to IscU 
and that the inhibitory effect is indeed translated to slower rate of cluster delivery to Grx4 which 
functions as an intermediate cluster carrier. Moreover, we did not see any effect of IscUI108M 
mutation in presence or absence of CyaY. 
 
RESULTS  
Both CyaY and IscUI108M do not affect quinonoid decay. It has been shown that FXN, 
as well as CyaY, accelerate quinonoid decay for eukaryotic cysteine desulfurase resulting in a 
facilitated production of persulfide on mobile loop cysteine of NFS1. This is in accordance with 
previously published result that both FXN and CyaY act as allosteric activators of eukaryotic 
cysteine desulfurase. To determine whether or not CyaY slows down quinonoid decay of 
prokaryotic cysteine desulfurase IscS, we monitored the formation and decay kinetics of quinonoid 
intermediate using stopped-flow. For this, we first determined the λmax (wavelength of maximal 
absorbance) for the quinonoid, aldimine and ketimine intermediates by scanning a 100 nm window 
in the range of 300 nm to 700 nm every 2 ms for 2 s (see methods). This gave us λmax of quinonoid 
and aldimine intermediate at 508 nm and 410 nm respectively (Figure III-1). Unfortunately, we 
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did not see a peak around 340 nm for ketimine intermediate in any of our runs. We decided to use 
340 nm to monitor the kinetics of ketimine intermediate nevertheless as this wavelength has been 
previously used to monitor ketamine intermediate126. As can be seen in Figure III-2a, b, c and d, 
quinonoid decay kinetics looks very similar for all the complexes and the rates of quinonoid decay 
were found to be very similar when fitted to consecutive B equation (Table III-1) with no effect 
of CyaY or IscUI108M on quinonoid decay. We also followed aldimine and ketimine formation 
kinetics by monitoring 410 nm and 340 nm respectively for SU and SUC complex. The kinetics 
were found to be similar in presence and absence of CyaY (Figure III-3). 
 
CyaY inhibits sulfur transfer from IscS to IscU but does not affect persulfide 
formation on IscS. Next, we wanted to see if CyaY has any effect on persulfide formation on IscS 
and IscU which is the next downstream step after PLP chemistry. We incubated IscS and IscU in 
presence and absence of CyaY with cysteine that contains trace amount of radioactive 35S-cysteine. 
We then quenched the reaction at different time points, separated proteins using HPLC (Figure 
III-4a) and quantified the amount of radioactivity via scintillation counting. The amount of 
radioactivity associated was then converted to the amount of persulfide on each protein using a 
standard curve. As can be seen in Figure III-4b, overall kinetics of persulfide formation on IscS 
in presence and absence of CyaY looked very similar but the extents of reaction completed were 
different. This corresponds really well with our previous observation that CyaY does not affect 
PLP chemistry, which directly results in persulfide formation on IscS. Contrary to this, CyaY 
significantly slowed down sulfur transfer from IscS to IscU (Figure III-4c). Interestingly, this 
contrasts with the effect of FXN on the human system where FXN accelerates sulfur transfer from 
NFS1 to ISCU2.  
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Both CyaY and IscUI108M do not affect cysteine desulfurase activity. Cysteine 
desulfurase activity for all four complexes (SU, SUC, SUI108M, SUI108MC) was measured according 
to previously published protocol. Cysteine desulfurase activity was comparable for all four 
complexes (Figure III-5). The absence of an inhibitory effect of CyaY is consistent with the lack 
of any effect on quinonoid decay and persulfide formation on IscS. 
 CyaY inhibits iron sulfur cluster formation on scaffold protein while IscUI108M has 
no effect. Iron sulfur cluster formation rates on scaffold protein (IscU or IscUI108M) in presence 
and absence of CyaY were determined using CD spectroscopy by monitoring the ellipticity change 
at 330 nm. Consistent with previously published results, CyaY was observed to strongly inhibit 
iron sulfur cluster formation on scaffold protein (Figure III-6 and Figure III-7). This inhibition 
can be explained as a direct consequence of inhibited sulfur transfer to scaffold protein. On the 
other hand, contrary to literature, the rates were comparable for SU and SUI108M in absence of 
CyaY. Moreover, CyaY did not accelerate iron sulfur cluster synthesis in the case of IscUI108M as 
had been suggested in the literature.  
CyaY does not affect iron sulfur cluster transfer from IscU to Grx4. Next, we wanted 
to explore if CyaY has any other effect(s) on cluster biosynthesis process in addition to inhibition 
of cluster assembly on scaffold protein IscU. To determine if CyaY has any effect on cluster 
transfer step, we reconstituted IscU (see methods) followed by addition of apo-Grx4 to initiate the 
reaction. The cluster transfer reaction was monitored using CD spectroscopy by monitoring 
ellipticity change at 450 nm (where Holo-Grx4 has much larger contribution compared to Holo-
IscU). The rates were found to be comparable with and without CyaY (Figure III-8 and Figure 
III-9). This shows that CyaY does not affect cluster transfer from holo-IscU to apo-Grx4. 
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CyaY inhibits one-pot cluster synthesis on Grx4 while IscUI108M has no effect. We 
further tested whether or not the inhibitory effect of CyaY on sulfur transfer step and consequently 
iron sulfur cluster assembly on scaffold protein results in inhibition of holo-Grx4 synthesis in a 
one-pot reaction where Holo-IscU is not pre-formed and cluster assembly on Grx4 is monitored 
by recording ellipticity change at 450 nm. CyaY strongly inhibited cluster synthesis on Grx4 
(Figure III-10 and Figure III-11). On the other hand, IscUI108M had no effect. This is in stark 
contrast to the effect of opposite mutation on human ISCU2M106I which has been shown to 
accelerate cluster transfer from ISCU2 to GRX5. 
 
DISCUSSION  
CyaY does not affect PLP chemistry and persulfide formation on IscS and cysteine 
desulfurase activity, unlike FXN. Although it has been well known for a long time that CyaY 
inhibits iron sulfur cluster synthesis on scaffold protein IscU75-76, 166, mechanism of the inhibition 
remained unknown. More specifically, it remained to be discovered which upstream step(s) is 
specifically inhibited by CyaY. Using a step-wise detailed analysis of the effects of CyaY on each 
and every upstream step and one downstream step, we sought to pinpoint the step(s) affected by 
CyaY. To accomplish this, we divided the whole pathway into four major steps – 1) persulfide 
formation, 2) sulfur transfer, 3) cluster synthesis and 4) cluster transfer (Figure III-9). We were 
aware that FXN activates persulfide formation on NFS1 by accelerating quinonoid decay. 
Therefore, we first tested if CyaY affects quinonoid decay. Using stopped-flow, we found that 
contrary to the effect of FXN in the human system, CyaY does not affect quinonoid decay of IscS 
both in presence and absence of IscU. Next, we examined if CyaY inhibits persulfide formation 
on IscS. Using the persulfide formation assay, we found that CyaY does not affect persulfide 
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formation on IscS unlike the effect of FXN on the human system where FXN was shown to 
accelerate persulfide formation on NFS1. This is consistent with our observation that CyaY does 
not accelerate quinonoid decay, which directly translates into persulfide formation. Therefore, this 
suggests that unlike in the case of FXN based activation of human cysteine desulfurase, CyaY does 
not perturb mobile loop trajectory of IscS. Again, consistent with lack of any effect of CyaY on 
persulfide formation on IscS, CyaY only had a minor inhibitory effect on cysteine desulfurase 
activity of IscS in presence of IscU (Also consistent with previous literature)76. 
 
CyaY slows down persulfide formation on IscU and subsequently iron sulfur cluster 
biosynthesis on IscU. In the same persulfide formation assay, we also found that in the presence 
of CyaY, persulfide formation on IscU was ~4 times slower. This is exactly opposite to the effect 
of FXN which, has been shown to accelerate persulfide formation on ISCU2. So how does CyaY 
inhibits persulfide formation on IscU. As we deduced earlier that CyaY does not perturb either 
mobile loop trajectory, we think CyaY may be causing a small conformational change in IscU, 
which results in misalignment of mobile loop trajectory and the cysteine residue on IscU that 
accepts sulfane sulfur. In absence of crystal structure of SUC complex it is extremely difficult to 
determine if this is the case. It is also possible that CyaY binds in the cleft between IscS and IscU 
and sterically prevents mobile loop cysteine from reaching to IscU and prevents sulfur transfer. 
The latter scenario has already been predicted using an in-silico study167. As expected, consistent 
with previous literature, CyaY was also found to strongly inhibit iron sulfur cluster formation on 
IscU. This shows that inhibition of sulfur transfer to scaffold protein directly translate into the 
inhibition of iron sulfur cluster biosynthesis on scaffold protein IscU and therefore provides 
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evidence in support of IscU persulfide being kinetically competent intermediate in iron sulfur 
cluster biosynthesis. 
Inhibitory effect of CyaY propagates further downstream to holo-Grx4 formation. 
After successfully determining sulfur transfer as the step that is primarily inhibited by CyaY 
resulting in slower iron sulfur cluster formation on IscU, we went further to determine - 1) if CyaY 
has any further role down-stream and 2) if this inhibitory effect translates to a slower rate of cluster 
synthesis on downstream acceptors. We found that CyaY does not affect cluster transfer from 
Holo-IscU to apo-Grx4 but inhibits one-pot cluster synthesis on Grx4. This shows that the 
inhibitory effect of CyaY on IscU cluster assembly slows down overall cluster biosynthesis 
process.  
 
The enigma: is CyaY an inhibitor or activator of iron sulfur cluster biogenesis? All 
the above results clearly showed that CyaY indeed inhibits iron sulfur cluster biosynthesis. This 
inhibitory effect originates in sulfur transfer step and propagated up to holo-Grx4 formation, which 
is an intermediate in cluster transfer pathway and distributes cluster to apo-targets (Figure III-12). 
This leads us to an important question - how does this inhibitory effect affect the fitness of an 
organism? We can predict that in absence of CyaY, an organism will produce iron sulfur cluster 
at a much faster rate. However, this also means transcriptional regulator IscR will also get iron-
sulfur cluster faster and will start repressing protein translation to prevent overproduction of iron 
sulfur cluster i.e. iron sulfur cluster production will remain normal in absence of CyaY and there 
would not be any usual phenotype such as growth defect, unusual activity of iron sulfur cluster 
containing proteins etc. That is exactly what has been reported for CyaY deleted strain when grown 
in normal rich media160, 162. However, a number of recent publications also reported that CyaY 
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deletion affects organism’s fitness under specific conditions and proposed that CyaY has a positive 
role in iron sulfur cluster biosynthesis. However, those reports did not discuss the inhibitory effect 
of CyaY in vitro and how this inhibitory effect may make CyaY important under those conditions. 
It has been shown that when YggX and ApbC genes were deleted together or separately, the 
presence of CyaY becomes crucial. YggX has been shown to sequester Fe(II) from participating 
in Fenton chemistry while keeping it available for iron-dependent cellular processes and thereby 
preventing oxidative damage168-169. ApbC is a member of MinD protein family and takes part in 
iron sulfur cluster metabolism process170-173. Understandably, absence of ApbC results in iron 
sulfur cluster metabolism defect and subsequent oxidative stress. When cells were grown in 
presence of H2O2, NO or paraquat, deletion of CyaY inhibited growth and this inhibition was 
exacerbated when YggX was also deleted163. Considering these results, CyaY definitely seems to 
have a positive effect on the fitness of organism under oxidative stress conditions. Interestingly, 
IscR deletion strain which cannot regulate iron sulfur production through transcriptional inhibition 
becomes hypersensitive to oxidative stress just like CyaY deletion strain174. It seems as if iron 
sulfur cluster acts as fuel for reactive oxygen species. Taken together, overproduction of iron sulfur 
cluster seems to be detrimental to the fitness of an organism in the event of oxidative stress and 
the inhibitory effect of CyaY on iron sulfur cluster production can explain the apparent positive 
effect of CyaY. At present, there is no direct evidence that overproduction of iron sulfur cluster 
can exacerbate oxidative stress by acting as fuel for it but if that is the case, it will change our 
understanding significantly. 
 
I108M variant of IscU behaves like wild-type. It had been shown by Dancis and co-
workers that a single point mutation (M → I) on scaffold protein in yeast can rescue all FXN 
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deletion phenotypes via bypassing FXN i.e. M → I mutation on scaffold protein in eukaryotes can 
make the organism FXN independent79, 175. As deletion of CyaY has no effect under normal growth 
condition, E. coli is CyaY independent. This led to study by Roche et al. to determine if the reverse 
mutation I → M would render E. coli CyaY-dependent165. They showed that cellular iron sulfur 
cluster level decreased for I → M mutation in E. coli and was even worse in absence of CyaY. 
Recently we determined that ISCU2M106I bypasses FXN by accelerating cluster transfer to GRX5 
in the human system. Here, we did a similar step-wise analysis to study the effect of IscUI108M on 
each step in the presence and absence of CyaY. More specifically, we tested if IscUI108M slows 
down any step and whether CyaY rescues the rate. We found that IscUI108M variant behaved just 
like wild type in all the steps and the effect of CyaY on cluster assembly of scaffold protein was 
also similar for IscUI108M and wt-IscU i.e. inhibitory rather than accelerating. Therefore, at present 
we still don’t have a mechanism that explains the effect of I → M mutation on scaffold protein of 
E. coli in vivo. 
 
S-transfer loop cysteine does it all: A common mechanism of E. coli and human 
cysteine desulfurase with differential regulation by FXN/CyaY.  It was known that S-transfer 
loop cysteine in human cysteine desulfurase NFS1 acts as a proton donor for quinonoid decay. 
We, therefore, tested if the S-transfer loop cysteine of E. coli cysteine desulfurase IscS can also 
act as a proton donor for the quinonoid decay step. We found that mutation of mobile loop cysteine 
to alanine abolished quinonoid decay (Figure III-3e, III-3f) and indeed serves as the proton donor 
for quinonoid to ketimine conversion in IscS and that a similar mechanism is in operation across 
all cysteine desulfurases. Furthermore, we reasoned that if quinonoid decay is inhibited in C328A 
variant of IscS, there should be an accumulation of quinonoid intermediate. Instead, we see a very 
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small quantity of quinonoid. A similar result was also obtained for the human system where 
SC381ADAecUF had a very small quinonoid accumulation but was comparable to IscS
C328A. We later 
realized this apparent anomaly is, in fact, the norm when we compared the total quinonoid 
accumulation with the rate of quinonoid decay of both E. coli and human cysteine desulfurases 
(Figure III-13). To explain that we reasoned that the s-transfer loop cysteine must also be 
facilitating some upstream step, most likely aldimine formation. When aldimine formation was 
monitored for IscSC328A and SC381ADAecUF, we found that the extent of aldimine formation is very 
low consistent with S-transfer loop cysteine’s participation in this step (Figure III-14 and III-15). 
Moreover, when we monitored ketimine formation for IscSC328A and SC381ADAecUF, we found very 
little accumulation of ketimine intermediate, which is again consistent with very slow quinonoid 
decay (Figure III-14 and III-15). Overall this reveals a common cysteine desulfurase mechanism 
in which S-transfer loop cysteine is doing everything – 1) facilitated aldimine formation, 2) 
accelerated quinonoid decay by acting as proton donor, 3) cleaved C-S bond of substrate cysteine 
by nucleophilic attack and generates persulfide on S-transfer loop cysteine and lastly 4) transfer 
sulfane sulfur in the form of persulfide to different sulfur acceptors. Further, we can speculate the 
nature of s-transfer loop cysteine’s participation in aldimine formation. As we understand, a 
facilitated gem-diamine formation requires nucleophilic attack of substrate cysteine α-amino group 
to electrophilic PLP. An absorption peak at 420 nm indicates PLP is protonated at pyridine and 
imine nitrogens and therefore, sufficiently electrophilic. Hence, we speculate s-transfer loop 
cysteine may be acting as a general base and facilitates deprotonation of the α-amine moiety of 
incoming substrate cysteine. As we have seen previously, all these steps that are facilitated by s-
transfer loop cysteine, are also accelerated by FXN whereas only the inter-protein sulfur transfer 
is inhibited by CyaY. This information reinstate the model of FXN based activation in which S-
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transfer loop is very flexible and adopts mostly non-productive loop trajectories in human 
monomeric cysteine desulfurase (SDAec or SDAecU) architecture. FXN binding limits the non-
productive loop trajectories and thereby accelerates all four steps affected by s-transfer loop 
cysteine. On the other hand, E. coli IscS is dimeric and here the other subunit is limiting non-
productive loop trajectories and therefore highly active in absence of FXN/CyaY. In fact, when 
compared rates, IscS dimer is actually much more efficient that SDAecUF. Furthermore, lack of 
any effect of FXN/CyaY on the PLP chemistry of IscS compared to activating effects of 
FXN/CyaY on SDAecU would strongly suggest differential binding of FXN/CyaY to dimeric IscS 
and monomeric SDAecU and establishes monomeric architecture of SDAec as physiologically 
relevant quaternary structure. 
 
 
MATERIAL AND METHODS  
Protein purification: IscS, IscU and CyaY were purified as described previously76. The 
QuikChange method (Stratagene) was used to introduce point mutation (I108M) into plasmid 
containing wt-IscU75. The mutation was confirmed by DNA sequencing (Gene Technology Lab, 
TAMU). IscUI108M was purified using the same protocol as wt-IscU. Grx4 was purified following 
literature procedure176. Unless otherwise stated, all the reactions were carried out in an anaerobic 
glove box (O2 < 1 ppm). 
 
Stopped-flow kinetics: Proteins (100 µM of each protein) were taken in one of the two 
syringes of the stopped-flow apparatus (KinTek Corporation). The other syringe contained 10 mM 
Cysteine. They were mixed together by pressing both the syringes simultaneously. Therefore, the 
final concentration of proteins and cysteine in the cuvette was 50 µM and 5 mM respectively. First, 
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λmax of each intermediate was determined by monitoring the change of absorbance every 2 ms in 
a 100 nm window. λmax for quinonoid and aldimine intermediate was found to be 508 nm and 410 
nm respectively, which were later used to monitor the kinetics of the intermediates. We could not 
detect a sharp peak around 340 nm for ketimine intermediate. We, therefore, used 340 nm as this 
wavelength has been used previously126. Next, the formation of aldimine, quinonoid and ketimine 
intermediate was followed by monitoring absorbance at 410, 508 and 340 nm respectively. For 
quinonoid kinetics, traces of 508 nm with time were fitted with Origin software (OriginLab) to 
Consecutive B equation [y = y0 + (k1*[A]0/(k2-k1))*(exp(-k1*t)-exp(-k2*t))], where k1 and k2 
are rate constants of the formation and decay of cys-qiononoid intermediate respectively. The rates 
were compared for IscS, IscSC328A, SU, SUC, SUI108M and SUI108MC. [R2 values: IscS (0.99), 
IscSC328A (0.83), SU (0.99), SUC (0.99), SUI108M (0.99), SUI108MC (0.99)]. Aldimine and ketimine 
(410 nm and 340 nm traces respectively) could not be fit adequately using Consecutive B equation 
as kinetics were more complex.  
 
Separation of proteins for sulfur transfer reaction: All the proteins (IscS, IscU and 
CyaY) were separated using C4 column (WAT011807, Waters) on HPLC (1260 Infinity, Agilent 
Technologies) at pH 2.0 (0.1 % TFA in water, Buffer A) by running a gradient of Buffer B (60% 
CH3CN, 40% Isopropanol, 0.1% TFA) from 30% to 70% within 40 min with 1mL/min flow rate. 
 
Measurement and quantification of radioactivity on proteins: The amount of 
radioactivity and in turn persulfide on IscS and IscU were determined using a similar procedure as 
described previously (CHAPTER II). Briefly, [35S]-cysteine (PerkinElmer, 10.2 μM, 1.00796 
mCi) was diluted 50 times by 1 mM non-radioactive cysteine resulting in a 204 nM final 
concentration of [35S]-cysteine in the stock solution and the ratio of [35S]-cysteine over cold 
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cysteine became 0.000204. After elution, the protein was passed through a mixer where it was 
combined with scintillation cocktail (BioCount 111182) and the signal was recorded with β-RAM 
radio-HPLC detector (Model 5C, LabLogic). Data collection and analysis were done with Laura 
software (LabLogic). The area under the scintillation peak (in CPM) was determined for each 
protein and converted into [35S] concentration associated with protein by using a standard curve 
plotted from known amounts [35S]-cysteine (and determining the area under the peak 
corresponding to cysteine). The total amount of persulfide on protein was obtained via dividing it 
by the [35S]-cysteine and non-radioactive cysteine ratio. 
 
Persulfide formation assay: Protein complexes (SU and SUC) were reacted with 30 μM 
cysteine (contains 0.0204% [35S]-cysteine) at 37°C followed by quenching at different time points 
starting from thirty seconds to one hour. Final protein concentrations were 30 μM IscS, 30 μM 
IscU and 75 μM CyaY (for SUC) with 50 µL reaction volume. The samples were quenched by 
mixing 150 µL quenching solution (conc. HCl and 6 M Guanidine hydrochloride (in 1:4 ratio, 
pH<1) to the 50 µL reaction. 150 µL of the resulting 200 µL was injected into HPLC for analysis. 
Amount of persulfide associated with IscS and IscU was calculated as described above and plotted 
against time. The data points were fitted using Origin software (OriginLab) to exponential rise 
equation [y=m1+m2*(1-exp (-m3*x))] where m3 value gives the apparent rate of formation. [R2 
values; IscS-SSH formation: 0.98 (SU), 0.98 (SUC); IscU-SSH formation: 0.98 (SU), 0.88 (SUC)]. 
 
Cysteine desulfurase activity: Cysteine desulfurase activities were measured for each 
complex (SU, SUC, SUI108M and SUI108MC) according to the published procedure (CHAPTER II). 
In short, a heating block was used to bring the temperature to 37°C. The proteins were mixed to a 
final concentration of 0.5 µM IscS, 2.5 µM IscU (or IscUI108M), 5 µM CyaY and 2 mM DTT 
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followed by incubation for 15 minutes on heating block already at 37°C, cysteine was then added 
and the reaction was then incubated for additional 6 min before quenching the 800 µL reaction 
mixture with 100 µL of N, N'-diphenyl-p-phenylenediamine (DPD, in 7.2 M HCl) and 100 µL of 
FeCl3 (in 1.2 M HCl) with final concentration of DPD and FeCl3 being 30 µM and 20 µM 
respectively. The samples were centrifuged after 20 min incubation at 37ºC and absorbance was 
measured at 670 nm. The amount of sulfide produced was determined for each data point using a 
standard curve. Rates ([S2-]/([SD]*min)) were plotted against the amount of cysteine added and 
fitted with Origin software (OriginLab) using Michaelis-Menten Equation to obtain kcat and KM 
values for each complex. [R2 values: SU (0.98), SUC (0.998), SUI108M (0.99), SUI108MC (0.99)]. 
 
CD spectroscopy: CD spectra were recorded on a Chirascan CD spectrometer (Applied 
Photophysics) using a 1 cm path length cuvette. Cuvettes were sealed with a rubber septum and 
electrical tape in a glove box (O2 < 1 ppm). The assays were run in 50 mM HEPES, 150 mM KCl, 
and 10mM MgCl2 (pH 7.5) at 22ºC. 
 
Cluster assembly assay on IscU: The assay constituted 8 µM IscS, 40 μM IscU (or 
IscUI108M), 50 μM CyaY, 200 μM Fe(NH4)2(SO4)2 and was initiated with the addition of 10 mM 
GSH and 100 µM cysteine using air-tight syringes. The cluster assembly rates were measured for 
SU, SUC, SUI108M, SUI108MC by monitoring the ellipticity change at 330 nm over time and fitting 
the initial data points using Kaleidagraph (Synergy software) to linear equation (y=m1x+m2), 
where m1 gives the initial rate of cluster synthesis. [R
2 values: SU (0.99), SUC (0.96), SUI108M 
(0.99), SUI108MC (0.99)]. 
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Cluster transfer assay from Holo-IscU to apo-Grx4: 20 μM IscU was re-constituted 
using 1 μM IscS, 40 µM CyaY, 400 μM Fe(NH4)2(SO4)2 and 40 μM cysteine with cysteine being 
the limiting reagent to inhibit any further cluster-synthesis. 40 μM Grx4 was then injected into the 
cuvette anaerobically using an air-tight syringe and the cluster transfer to the latter was followed 
by monitoring the ellipticity change at 450 nm over time and fitting the initial data using 
Kaleidagraph (Synergy software) to linear equation (y=m1x+m2), where m1 gives the initial rate 
of cluster transfer from Holo-IscU to apo-Grx4. 450 nm was chosen as the wavelength to monitor 
the transfer due to minimal contribution from holo-IscU at that wavelength. The rates were 
compared for SU, SUC. [R2 values: SU (0.93), SUC (0.93)]. 
 
One-pot Cluster synthesis on apo-target: 0.5 µM IscS, 20 μM IscU (or IscUI108M), 40 
µM CyaY, 40 μM Grx4, 200 μM Fe(NH4)2(SO4)2 and initiated by the addition of 10 mM GSH and 
100 μM cysteine. Cluster formation on Grx4 was then measured for SU, SUC, SUI108M, SUI108MC 
by monitoring the change of ellipticity at 450 nm over time and fitting the initial time points using 
Kaleida graph (synergy software) to linear equation (y=m1x+m2), where m1 gives the initial rate 
of cluster formation on Grx4. [R2 values: SU (0.99), SUC (0.94), SUI108M (0.99), SUI108MC (0.62)].  
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Figure III-1. Wavelengths of maximal absorbance 
(λmax) of PLP intermediates were determined by 
stopped flow. Reaction contained 50 µM IscS and 5 
mM cysteine (final concentration). These wavelengths 
were used to determine the kinetics of intermediates for 
all the complexes. 
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Figure III-2. Both CyaY and IscUI108M does not affect the rate of quinonoid formation 
and decay. The formation and decay of quinonoid intermediate were monitored by stopped 
flow at 508 nm wavelength. Reaction contained 50 µM all the proteins (IscS, 
IscU/IscUI108M, CyaY) and 5 mM cysteine (final concentrations). The rates were obtained 
by fitting the data to the equation [y=y0 + A*(m1/(m3-m2))(exp(-m2*x)-exp(-m3*x))], 
where m2 and m3 values give the apparent rate of formation and decay of the quinoid 
intermediate respectively.  
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Figure III-3. CyaY does not affect the rate of aldimine and ketimine formation and 
decay. The formation and decay of aldimine and ketimine intermediates were monitored 
by stopped flow at 410 and 340 nm wavelength respectively. Reaction contained 50 µM 
all the proteins (IscS, IscU, CyaY) and 5 mM cysteine (final concentration). A rate constant 
for the formation and decay of the intermediates could not be determined as the data could 
not be fitted to the equation [y=y0 + A*(m1/(m3-m2))(exp(-m2*x)-exp(-m3*x))], where 
m2 and m3 values would have given the apparent rate of formation and decay of the 
intermediate respectively. 
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Figure III-4. CyaY does not affect the rate of persulfide formation on IscS but slows 
down persulfide formation on IscU. (a) Separation of proteins by HPLC. 50 µM IscS, 
150 µM IscU and 50 µM CyaY were loaded onto Deltapack C4 column after diluting with 
quenching solution in 1:3 ratio to a final volume of 200 µL (see method). Chromatogram 
shows that IscS and IscU are well separated. Although CyaY co-elutes with IscS, does not 
affect our analysis. (b), (c) Persulfide formation on IscS and IscU in presence and absence 
of CyaY was monitored by reacting 30 uM of IscS, IscU, CyaY and Cysteine (containing 
0.204% 35S-cysteine) at 37ºC for different time (in 0 - 20 min range). The samples were 
analyzed with HPLC and scintillation cocktail after quenching with quenching solution 
(1:4 mixture of conc. HCl and 6M guanidine hydrochloride) at given time points. The area 
under IscS and IscU in scintillation trace were converted into amounts of persulfide using 
a standard curve made from 35S-cysteine standard. The data were fitted with exponential 
rise equation [y=m1+m2*(1-exp (-m3*x))] where m3 value gives the apparent rate of 
formation which is plotted in (d). 
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Figure III-5. Both CyaY and IscUI108M does not affect cysteine desulfurase activity. 
The reactions contained 0.5 µM IscS, 2.5 µM IscU/IscUI108M, 5 µM CyaY, 4 mM D,L-DTT. 
Reactions were initiated by adding cysteine and incubated for 6 min before quenching with 
DPD and FeCl3 solution. Solutions were further incubated for 20 min. Then the samples 
were centrifuged and absorbances at 670 nm were measured, which were converted to 
concentration of sulfide using a standard curve made from known amount of sulfide. The 
data points were fitted to Michaelis-Menten equation (y = m1*x/(m2 + x)), where m1 and 
m2 are kcat and KM respectively. 
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Figure III-6. CyaY inhibits cluster assembly on IscU/IscUI108M. Reaction consists of 8 
µM IscS, 40 µM IscU (a) or IscUI108M (b), 50 µM CyaY, 200 µM Fe2(NH4)2SO4 and 
initiated by the addition of 10 mM GSH and 100 µM cysteine. The rate is calculated by 
monitoring the change of ellipticity at 330 nm and fitting the initial data points to linear 
equation and plotted in (c). 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-7. Full reaction showing the effect of CyaY on cluster synthesis on either 
IscU or IscUI108M. Reaction consists of 8 µM IscS, 40 µM IscU (a) or IscUI108M (b), 50 
µM CyaY, 200 µM Fe2(NH4)2SO4 and initiated by the addition of 10 mM GSH and 100 
µM cysteine. The formation of cluster on IscU/IscUI108M is monitored by the change of 
ellipticity at 330 nm. The fit of initial linear portion to a linear equation to determine rate 
is shown in Figure III-6. 
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Figure III-8. CyaY does not affect the rate of cluster transfer from Holo-IscU to apo-
Grx4. (a) Reaction contained 0.5 µM IscS, 20 µM Holo-IscU and 10 mM GSH and 40 µM 
CyaY and was initiated by the addition of 40 µM Grx4. The transfer of cluster from Holo-
IscU to apo-Grx4 is measured by monitoring ellipticity at 450 nm. (b) The rates were 
obtained by fitting the initial data points to linear equation, which is plotted in (c). 
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Figure III-9. Full spectra of cluster transfer 
reaction from holo-IscU to apo-Grx4 before and 
after addition of apo-Grx4. Dotted line is before apo-
Grx4 addition and solid line is after apo-Grx4 addition. 
Blue traces are for reactions without CyaY and red 
traces are for reactions with CyaY. 
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Figure III-10. CyaY inhibits one pot cluster assembly on Grx4 while IscUI108M has no 
effect. Reactions included 0.5 µM IscS, 20 µM IscU (a) or IscUI108M (b), 40 µM CyaY, 
200 µM Fe2(NH4)2SO4 and 40 µM Grx4. The reaction was initiated with addition of 100 
µM cysteine and 10 mM GSH. Cluster assembly on apo-Grx4 was measured by monitoring 
ellipticity at 450 nm. The rates were obtained by fitting the data to linear equation and 
plotted in (c). 
 87 
 
 
 
 
 
 
 
 
Figure III-11. Full spectra of one-pot cluster synthesis reaction on Grx4 before and 
after addition of (Cysteine + GSH) mixture, which was used to initiate the reaction. 
Dotted line is before initiation of reaction and solid line is after initiation of reaction. Blue 
traces are for reactions without CyaY and red traces are for reactions with CyaY. IscU (wt) 
was used as scaffold for (a) and (b) and IscUI108M was used as scaffold for (c) and (d).  
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Figure III-12. Schematic diagram showing the effect of CyaY and IscUI108M on each 
step. CyaY inhibits only sulfur transfer step and IscUI108M has no effect. 
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Figure III-13. Correlation between quinonoid accumulation and rate of quinonoid 
decay. Faster quinonoid decay strongly correlates with greater accumulation of quinonoid 
intermediate which is intuitively opposite. As we have shown this is due to S-transfer loop 
cysteine’s participation in aldimine formation in the upstream step. 
 90 
 
 
 
 
 
 
Figure III-14. S-transfer loop cysteine is the proton donor for quinonoid decay. The 
formation and decay of quinonoid, aldimine and ketimine intermediate were monitored by 
stopped flow at 508, 410 and 340 nm wavelength respectively. Reaction contained 50 µM 
of cysteine desulfurase (IscS or IscSC328A) and 5 mM cysteine (final concentrations). The 
rates were obtained by fitting the data to consecutive B equation [y=y0 + A*(m1/(m3-
m2))(exp(-m2*x)-exp(-m3*x))], where m2 and m3 values give the apparent rate of 
formation and decay of the intermediates respectively. Ketimine kinetics is too complex to 
fit adequately using consecutive B equation. (a) Quinonoid kinetics of wt-IscS. (b) 
Quinonoid kinetics of IscSC328A variant. The decay of quinonoid intermediate is severely 
inhibited. (c) Aldimine kinetics of IscSC328A variant. The maximum amount of aldimine 
formed is much smaller compared to wt-IscS. However, the rate of aldimine decay is very 
similar to wt-IscS. (d) Ketimine kinetics of IscSC328A variant. Ketimine formation is very 
slow and consistent with very slow quinonoid decay. 
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Figure III-15. S-transfer loop cysteine of NFS1 also facilitates cys-aldimine formation 
and accelerates cys-quinonoid decay by proton donation. (a), (b) and (c) Cys-aldimine 
formation takes place in the dead time of the instrument. So, we typically don’t see. 
However, starting amount of cys-aldimine is much higher for SDAecUF than that of both 
SDAecU and S
C381ADAecUF, which are comparable. This show that s-transfer loop cysteine 
somehow participates in aldimine formation. In contrast, aldimine decay rates are 
comparable for all three complexes. Since aldimine decay is caused by Cα proton 
abstraction, this data shows s-transfer loop cysteine does not participate as general base for 
Cα proton abstraction. (d), (e) and (f) Cys-ketimine if formed to a greater extent in the case 
of SDAecUF than that of SDAecU and S
C381ADAecUF, which is consistent with previously 
published quinonoid decay kinetics that faster quinonoid decay leads to greater 
accumulation of ketimine intermediate. 
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Table III-1. Kinetic data for Fe-S assembly complexes (E. coli). 
 
      
Relative Rate with respect 
to SU 
  SU SUC SUI108M SUI108MC SU SUC 
PLP 
Chemistry 
Cys-quinoid 
formation (s-1) 
79.27 ± 1.32 60.98 ± 0.64 70.96 ± 1.07 44.88 ± 0.6 1 0.77 
Cys-quinoid 
decay (s-1) 
11.21 ± 0.1 11.48 ± 0.07 12.36 ± 0.1 12.34 ± 0.11 1 1.024 
Persulfide 
formation 
reactions with 
[35S]-Cys 
(min-1) 
Persulfide 
formation on IscS 
2.59 ± 0.33 2.71 ± 0.54 ND ND 1 1.046 
Persulfide 
formation on IscU 
1.27 ± 0.17 0.36 ± 0.15 ND ND 1 0.283 
Cysteine 
desulfurase 
activity 
kcat (min
-1) 5.35 ± 0.17 3.96 ± 0.03 4.82 ± 0.09 4.26 ± 0.09 1 0.74 
KM (µM) 14 ± 2 14.4 ± 0.6 12 ± 1 19 ± 2 1 1.029 
Cluster 
synthesis 
Cluster formation 
on ISCU2 
(mdeg/min) 
4.6 ± 0.1  0.26 ± 0.01 4.1 ± 0.2 0.54 ± 0.01 1 0.057  
Cluster 
transfer 
Cluster transfer 
ISCU2 to GRX5 
(mdeg/min) 
0.067 ± 
0.006 
0.068 ± 
0.007 
ND ND 1 1.015 
Complete 
reaction 
Cluster synthesis 
& transfer to 
GRX5 
(mdeg/min) 
0.164 ± 
0.002 
0.046 ± 
0.003 
0.177 ± 
0.004 
0.02 ± 0.004 1 0.28 
ND – Not determined. 
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Table III-2. Rates for individual steps in the PLP chemistry of cysteine desulfurase. 
 
 
Rate of Cys-
aldimine Decay 
(s-1) 
Rate of Cys-
quinonoid 
Formation (s-1) 
Rate of Cys-
quinonoid Decay 
(s-1) 
Relative rate 
of quinonoid 
decay 
IscS - 80.71 ± 1.25 11.05 ± 0.09 9.3 
IscSC328A 2.18 ± 0.03 77.42 ± 2.4 0.082 ± 0.003 0.069 
SDAecU 1.82 ± 0.05 19.5 ± 0.5 1.19 ± 0.03 1 
SDAecUF 1.70 ± 0.01 17.5 ± 0.4 4.80 ± 0.07 4.03 
SC381ADAecUF 2.84 ± 0.05 58.76 ± 2.04 0.099 ± 0.004 0.083 
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CHAPTER IV                                                                                                                        
DIMER TO MONOMER TRANSITION AND NOT ACTIVE SITE RESIDUES EXPLAINS 
LOW ACTIVITY OF NFS1 
 
INTRODUCTION 
 One of the most intriguing problem in the field of iron sulfur cluster biosynthesis is the 
differences between prokaryotic and eukaryotic system. Prokaryotic cysteine desulfurase (IscS) 
does not require accessory proteins for stability as in the case of eukaryotic cysteine desulfurase 
(NFS1), which requires ISD11 and ACP21, 28, 122. Together NFS1, ISD11 and ACP form a stable 
cysteine desulfurase complex called SDA33, 122, 177. Moreover, the stable SDA complex is 
significantly less active (~ 8 times) than the prokaryotic counterpart (IscS)76. Furthermore, while 
eukaryotic iron sulfur cluster biosynthesis is activated by FXN70, prokaryotic iron sulfur cluster 
biosynthesis is actually inhibited by CyaY75 and the activation/inhibition mechanism is very 
different as previously determined. Earlier studies determined that this difference is due to the type 
of cysteine desulfurase used i.e. in presence of prokaryotic cysteine desulfurase both FXN and 
CyaY inhibits iron sulfur cluster biosynthesis whereas in presence of eukaryotic cysteine 
desulfurase both FXN and CyaY activates iron sulfur cluster biosynthesis76. The discovery of 
human cysteine desulfurase complex (SDA) crystal structure (PDB 5USR) revealed that although 
the monomer subunits are very well aligned (Figure IV-1), in dimer, the cysteine desulfurase 
subunits are arranged very differently and there is almost no interaction between the two subunits 
(subunits are bridged by ISD11) contrary to extensive interaction between the two IscS subunits33, 
143. This architectural difference has provided a rationale for the inherent high activity of IscS, low 
activity of SDA and activation of SDA by FXN in presence of ISCU2. We hypothesize that in 
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open architecture (SDA architecture), S-transfer loop can adopt any number of trajectories, most 
of which are unproductive. In case of IscS, the other subunit provides restraint on the number of 
trajectories and thereby increases the probability of adopting productive loop trajectory 
significantly. This results in high activity of IscS. In case of SDAUF, FXN functions as pseudo-
subunit of NFS1 and function similar to the other subunit of IscS although to a lesser efficiency. 
This hypothesis then leads to prediction that if we can manage to weaken the dimer interface of 
IscS by changing some dimer interface residues resulting in monomer formation, that activity of 
that IscS monomer will be lower (similar to SDA). If we add FXN/CyaY to the monomer we would 
see an increase in activity (provided they bind to the monomer). Furthermore, if we mutate the 
NFS1 dimer interface residues to corresponding IscS residues, we would generate and IscS type 
dimer of NFS1, which would have high activity similar to IscS. Alignment of IscS and NFS1 
monomer structures revealed some probable residues that may be important for dimerization. We 
found a pair of histidine-glutamine residues (H247, Q248 of IscS) at the dimer interface and 
hydrogen bonds with the same residues from the other subunit (Figure IV-2). These residues are 
very well conserved among gamma-proteobacteria but absent in eukaryotes and alpha-
proteobacteria (ancestors of mitochondria) where they were replaced by residues that cannot form 
hydrogen bond (Figure IV-3). Most interestingly we found a serine residue in position 10 of IscS 
is glutamine 64 in NFS1. This glutamine is absolutely conserved in eukaryotes. However, in 
prokaryotes it is mostly serine, alanine and glycine (Figure IV-4). In monomeric Cory architecture 
of NFS1 (PDB 5USR), this glutamine is hydrogen bonded to a conserved histidine that binds PLP 
phosphate. In IscS however, a conserved threonine (T12) hydrogen bonds with the same conserved 
histidine (Figure IV-5a). This threonine to glutamine switch results in a big conformational 
change in the N-terminus, which now collide with the other subunit (Figure IV-5b). This led up 
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to hypothesize that IscSS10Q variant may have a week dimer interface. However, the discovery of 
a second crystal structure of SDA (PDB 5WGB) with IscS type architecture raised question on this 
monomer-dimer hypothesis specially since that material was also shown to have low activity140. 
This prompted us to look for some other ways to explain this low activity of SDA and FXN based 
activation. We reasoned that it is possible that some active site residue plays key role in cysteine 
desulfurase activity, which is positioned in an active conformation in IscS resulting in high activity 
but in case of SDA, it is in inactive conformation resulting in low activity. FXN binding to SDA 
causes a conformational change of that residue to active conformation, thereby increasing cysteine 
desulfurase activity. However, the active site of both IscS and NFS1 looks identical. All the 
residues interacting with PLP or likely to interact with cysteine substrate are identical. Only there 
are some minor difference in the second shell PLP interacting residues (Figure IV-6). 
 Here, we have looked at the effects of second shell PLP interacting residues and dimer 
interface residues on cysteine desulfurase activity. More specifically whether or not interchanging 
IscS and NFS1 residues would result in inter-converting IscS into NFS1. By monitoring pre-steady 
state kinetics using stopped flow, steady state cysteine desulfurase activity using methylene blue 
assay and monomer formation using analytical size exclusion chromatography (S200) we have 
found out that second shell PLP interacting residues do not perturb the system significantly except 
for C158 of NFS1, which is conserved among eukaryotes and hydrogen bonds to the conserved 
histidine residue that is п-stacking PLP. Mutation of this cysteine to alanine (as in IscS) results in 
loss of PLP during purification. S10Q variant of IscS shows weaker dimer binding and 
significantly low activity. Further analysis with analytical SEC shows that the activity of IscSS10Q 
is proportional to dimer concentration, strongly indicating monomer formation as the cause of low 
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activity and in turn most likely the Cory-architecture (PDB 5USR) as physiologically relevant 
architecture. 
 
RESULTS 
2nd shell PLP interacting residues of IscS are not responsible for high activity.   The 
effects of second shell PLP interacting residues were measured by comparing their effects on 
quinonoid decay and cysteine desulfurase activity. As can be seen in Figure IV-7, Figure IV-8 
and Table IV-1, there are small changes in the cysteine desulfurase activity, which corresponds 
nicely with the changes in rate of quinonoid decay. SC158ADAec was colorless after purification 
indicating PLP was lost during purification. Attempt to reconstitute PLP bound form resulted in 
twice the amount of PLP bound to protein even after extensive desalting. In presence of ISCU2 
and FXN, this material showed very low activity (kcat) and very high KM indicating reconstitution 
with extra PLP may have compromised its function. Therefore, we cannot confidently say if 
C158A mutation results in low activity other that it definitely affects PLP binding. Since we don’t 
see similar effect in IscS where this residue is alanine, it indicates may be NFS1 is monomer under 
reaction condition and a combination of monomeric architecture and an alanine residue is required  
for weaker PLP binding. 
Dimer interface mutants cause low activity. When the effects of dimer interface residues 
were measured on quinonoid decay and cysteine desulfurase activity, it was found that there was 
a small decrease in quinoid decay but a significant decrease in cysteine desulfurase activity (Figure 
IV-9, Figure IV-10, Table IV-2). To determine if the lower activity was due to monomer-dimer 
equilibrium, the dependence of activity on enzyme concentration were measured for both IscS and 
IscSS10Q. It was found that in the range of 0.25 to 5 µM, specific activity ([S2-]/([Enzyme]*min)) 
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remained same for IscS while increased with increasing concentration for IscSS10Q. Fitting the 
observed rate (v) vs total enzyme concentration (Et) using Equation (4), binding constants were 
obtained at 0.01 and 1 µM for IscS and IscSS10Q respectively (Figure IV-11).  
Monomerization of dimer interface mutants is the cause of low activity. Binding 
constant of 0.01 and 1 µM predicted that in the range of 0.5 to 10 µM, IscS will be mostly dimeric 
and IscSS10Q will have a large portion of monomer (Figure IV-12). In order to verify that, 
analytical size exclusion (S200) was used to separate monomer from dimer and estimate the 
percentage of the dimer. As predicted, 90% of IscS was estimated to be the dimer in all the 
concentrations. On the other hand, IscSS10Q showed increased amounts of dimed as concentrations 
were increased. When compared with specific activity, estimated amounts of dimer percentage 
from analytical SEC (S200) showed the same trend. For IscSS10Q, as dimer percentage increased, 
specific activity also increased (Figure IV-13a). For IscS, dimer percentage remained same, 
specific activity also remained same (Figure IV-13b).  
 
DISCUSSION 
Difference between prokaryotic and eukaryotic cysteine desulfurase is an enigmatic 
problem. The cause is unknown and the consequences are profound. Here we have attempted to 
determine the cause of this dime monomer conversion. Surprisingly we found a serine residue 
(S10) when mutated to glutamine can weaken dimer interface significantly (Kd changed 100 timed 
from 0.01 µM to 1 µM). This weakened dimer interface leads to lower dimer concentration 
resulting in lower activity. Side by side comparison of specific activity and dimer percentage 
(obtained from S200) clearly showed specific activity is directly dependent on dimer 
concentration. This nicely fits into the idea that in monomeric architecture cysteine desulfurase 
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will have very low activity (basal level activity). Only when cysteine desulfurase have closed 
architecture (as in IscS) it becomes highly active. In case of IscS, it is a homodimer, but in case of 
the human system, we predict it is heterodimer with FXN playing the role of other cysteine 
desulfurase subunit and binding in the same surface that is normally occupied by the other subunit. 
We also found that second shell PLP interacting residues do not affect cysteine desulfurase activity 
significantly, demonstrating monomerization is the sole cause of low activity of NFS1. However, 
in our present study, we were not able to make monomeric IscS exclusively. From activity assay, 
we found the other dimer interface mutant pair (H247P, Q248L) lowered the kcat value to half of 
wild-type. This strongly indicates that this pair also contributes towards dimer stability (not to the 
same extent as of S10Q). We, therefore, predict if we make a triple mutant, dimer interface will be 
even weaker and we may be able to achieve monomeric IscS exclusively. It will also be interesting 
to see if this low activity monomer can be activated by FXN/CyaY and if can be, whether or not 
the activation depends on the presence of ISD11. At present we know nothing about ISD11 other 
than that it is absolutely required for NFS1 stability. Why NFS1 became entirely dependent on 
ISD11 during evolution is still a mystery. We are hopeful this monomer-dimer interconversion 
experiments will provide significant insight into active cysteine desulfurase complex formation 
along with the exact function of each of members of the complex and lastly a sneak peek into the 
past. 
 
MATERIALS AND METHODS 
Protein Preparations. All the proteins were purified as described previously. The 
QuikChange protocol (Agilent) was used to introduce the point mutations. Protein variants were 
purified similarly to wild types. Unless otherwise stated, all reactions were carried out in an 
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anaerobic glove box (MBRAUN; maintained at ~14 °C with O2 < 1 ppm). Protein concentrations 
were estimated using the following extinction coefficients: IscS and SDAec (wt and variants) using 
6.6 mM-1cm-1 at 388 nm (in 0.1 M NaOH), ISCU2 using 8490 M-1cm-1 at 280 nm, FXN using 
26030 M-1cm-1 at 280 nm, Protein variants were assumed to have the same extinction coefficient 
as the native proteins.  
Cysteine desulfurase activity measurements. Cysteine desulfurase activities were 
measured for each complex using a slightly modified methylene blue assay.70, 148 Protein 
complexes were generated in assay buffer (50 mM HEPES, 250 mM NaCl, pH 7.5) with final 
concentrations of 0.5 µM cysteine desulfurase [IscS or NFS1 (as SDAec) or their variants], 1.5 µM 
ISCU2, and 1.5 µM FXN (when included). The complexes were combined with 4 mM D,L-DTT 
and incubated for 15 min anaerobically on a heating block at 37 °C. Different concentrations of L-
cysteine were added, incubated for 6 min, and quenched with 20 mM N,N'-diphenyl-p-
phenylenediamine (DPD) (in 7.2 M HCl) and 30 mM FeCl3 (in 1.2 M HCl). The samples were 
centrifuged after 20 min and the absorbance was measured at 670 nm. The amount of sulfide 
produced was determined for each data point using a standard curve. Rates ([S2-]/([NFS1]*min)) 
were plotted against the amount of L-cysteine added and fit to the Michaelis-Menten equation 
using Kaleidagraph to obtain kcat and KM parameters. For determining binding constant of 
monomer subunits by cysteine desulfurase activity measurement, concentration of IscS or IscSS10Q 
were varied keeping cysteine and D,L-DTT concentration fixed at 1 mM and 4 mM respectively. 
For 5 and 10 µM IscS, 2.5 mM cysteine and 10 mM D,L-DTT was used. Everything else about the 
methylene blue assay was kept the same. For samples with A670 >1, samples were remeasured 
after diluting 10 times with blank solution (800 µL assay buffer + 100 µL of 20 mM N,N'-diphenyl-
p-phenylenediamine (DPD) (in 7.2 M HCl) + 100 µL of 30 mM FeCl3 (in 1.2 M HCl). Rate (µM 
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[S2-]/min) were plotted against protein concentration (µM) and the data were fitted to Equation (4) 
with the assumption that all the activity is due to dimer and monomer has no activity. The fit gave 
us binding constant of the two monomer subunits. This calculated binding constant and Equation 
(2), (3) were used to estimate monomer and dimer concentrations at a given protein concentration 
respectively178.  
Analytical size exclusion (S200) chromatography. IscS and IscSS10Q proteins were 
diluted to 600 µL final volume (in assay buffer) to a final concentration of 0.5, 1 2.5, 5 and 10 µM 
in presence of 2 mM TCEP (at pH 8.0). 500 µL from this sample was injected into an S200 column 
(Superdex 200 10/300 GL, GE Healthcare Life Sciences) and eluted with a flow rate of 0.5 
mL/min). The area under the monomer and dimer peak was estimated using UNICORN software 
(default software of Acta FPLC, GE Healthcare Life Science).  
Stopped-flow kinetics of quinonoid intermediate. Kinetics of quinonoid intermediate 
was monitored and analyzed as previously. In short,100 µM protein complex in assay buffer (50 
mM HEPES, 250 mM NaCl, pH 7.5) was placed in one of the syringes of the stopped-flow 
apparatus (KinTek Corporation). The other syringe contained 10 mM L-cysteine. The samples 
were mixed by simultaneously pressing both syringes. Formation and decay of quinonoid 
intermediate were followed by monitoring changes in absorbance at 508 nm. 508 nm absorbance 
trace with time were fitted with Origin software (OriginLab) to a consecutive B equation [y = y0 
+ (k1*[A]0/(k2-k1))*(exp(-k1*t)-exp(-k2*t))], where k1 and k2 are rate constants of the formation and 
decay of intermediates respectively.  
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Figure IV-1. Alignment of IscS and NFS1 monomer 
subunits. Overall the tertiary structures are very similar. 
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Figure IV-2. Bridging histidine glutamine 
pair. Green and cyan denotes different subunit. 
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Figure IV-3. Distribution of amino acid residues in the position equivalent to 247, 248 
of IscS among proteobacteria. Beta and Gamma proteobacteria (e.g. E coli) has mostly 
HQ pair in these positions whereas Delta, Epsilon and Alpha proteobacteria (which share 
last common ancestor with mitochondria) has other amino acids (Non-HQ) that cannot 
form hydrogen bonds at the dimer interface. Eukaryotes also has non-HQ residues 
exclusively. 
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Figure IV-4. Distribution of amino acid residues in the position equivalent to 10 of 
IscS among proteobacteria. Beta and Gamma proteobacteria (e.g. E coli) has smallest 
amino acids such as serine (S), alanine (A) and glycine (G) in this position whereas Epsilon 
and Alpha proteobacteria (which share last common ancestor with mitochondria) has 
asparagine or glutamine. Eukaryotes has glutamine exclusively. 
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Figure IV-5. Effect of serine to glutamine mutation at position 10 of IscS. (a) 
Conserved histidine interacts with PLP phosphate group. That histidine is hold in place by 
either threonine (closed architecture) or glutamine (open architecture). (b) Shows the effect 
of the serine to glutamine switch. Towards C-terminus both IscS and NFS1 shows very 
good alignment. After the switch, there is big conformational change in N-terminus. When 
glutamine is the residue interacting with conserved histidine (Purple), the conformation 
that N-terminus adopts would cause collision with some residues of the other subunit of 
IscS (shown in yellow). 
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Figure IV-6. Comparison of active sites of IscS and NFS1. The active site looks very 
similar. Most of the residues are identical and they can be aligned in 3D very well. Blue, 
green and red circles pointing towards residues that are different between IscS and NFS1. 
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Figure IV-7. Comparison of quinonoid decay kinetics. Both D79N and D79N-A106C 
variants shows quinonoid decay kinetics similar to IscS and much faster than that of 
SDAecUF. 
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Figure IV-8. Comparison of cysteine desulfurase activity. IscSD79N has similar activity 
as wt whereas IscSD79N, A106C has slightly low activity but still much more active that SDAec, 
which has kcat of ~1 per min. 
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Figure IV-9. Comparison of quinonoid decay kinetics. Both H247P-Q248L and S10Q 
variants shows quinonoid decay kinetics similar to IscS and much faster than that of 
SDAecUF. 
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Figure IV-10. Comparison of cysteine desulfurase activity. Both IscSH247P, Q248L and 
IscSS10Q has low activity compared to wt. The activity of IscSS10Q is very close to that 
SDAec, which has kcat of ~1 per min. 
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Figure IV-11. Binding constant determination by dependence of enzyme 
concentration on cysteine desulfurase activity. The data were fitted to Equation (4) to 
obtain binding constants of monomer subunits. 
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Figure IV-12. Chromatogram of analytical size exclusion chromatography of IscSS10Q. 
As the protein concentration is lowered, monomer peak (~15.5 mL) grows while the dimer 
peak (~ 14 mL) shrinks indicating a monomer dimer equilibrium. 
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Figure IV-13. Specific activity correlates well with dimer concentration. Dimer % was 
estimated from analytical size exclusion chromatography. It was then plotted against 
protein concentration along with specific activity. This shows dimer concentration dictates 
specific activity. 
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Table IV-1. Effect of PLP second shell interacting residues on kcat and quinonoid decay 
Organism Complex kcat (min
-1
) KM (µM) 
Quinonoid 
decay (s
-1
) 
E. coli 
IscS 8.2 ± 0.1 20 ± 1 9.77 ± 0.09 
IscS
D79N 9.2 ± 0.2 26 ± 2 12.44 ± 0.12 
IscS
D79N, A106C 6.66 ± 0.07 17.6 ± 0.7 7.46 ± 0.07 
Human 
SDAecUF 10.07 ± 0.15 11.6 ± 0.9 4.8 ± 0.06 
S
N131D
DAecUF ND ND ND 
S
N131D, A234T
DAecUF 7.1 ± 0.2 58 ± 7 ND 
S
N131D, A234T, C158A
DAecUF 0.26 ± 0.01 188 ± 37 ND 
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Table IV-2. Effect of dimer interface residues of IscS on kcat and quinonoid decay  
Organism Complex kcat (min-1) KM (µM) Quinonoid decay (s-1) 
E. coli 
IscS 8.2 ± 0.1 20 ± 1 9.77 ± 0.09 
IscSH247P, Q248L 4.12 ± 0.07 18 ± 2 7.87 ± 0.06 
IscSS10Q 1.90 ± 0.05 11 ± 2 7.13 ± 0.05 
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CHAPTER VI                                                                                                                         
CONCLUSION AND FUTURE DIRECTION 
 
Iron sulfur cluster is one of the smallest cofactors and plays an essential role in human 
health. Defect in iron sulfur cluster biosynthesis is responsible for several diseases such as 
Friedreich’s ataxia (FRDA), ISCU myopathy, X-linked sideroblastic anemia179. However, the 
biosynthetic mechanism has remained mostly obscured. Over last 25 years there have been 
considerable progress in identifying different pathways and proteins involved in iron sulfur cluster 
biosynthesis. But the molecular details are still missing. This project started to figure out exactly 
how iron and sulfurs are assembled to make iron sulfur cluster and the function of each and every 
protein involved in this pathway. More specifically we wanted to know the exact function of 
frataxin and ferredoxin. Frataxin was discovered in 1996 in the process of discovering the cause 
of Friedreich’s ataxia38. Since then, much progress was made through cell biology studies, but 
those studies also generated much controversies. Frataxin was initially assigned iron-based 
function (iron storage, iron chaperon, iron donor etc.) based on the phenotypes of iron 
accumulation in mitochondria and elevated amounts of ROS production by Fenton chemistry56, 61-
62, 64. Majority of these studies were conducted on yeast and it was later revealed that yeast frataxin 
is unusually unstable (Tm = 35.8°C) and these effects are not observed with mature human frataxin 
(81-210)66. Next three very important studies changed the course of frataxin’s function discovery. 
First, in 2009, frataxin (CyaY) was shown to inhibit iron sulfur cluster biosynthesis in E. coli 
contrary to observed acceleration by eukaryotic frataxin75. This raised serious question about the 
iron donor role as one would expect frataxin to accelerate and not inhibit iron sulfur cluster 
biosynthesis if its function is indeed to provide iron. Second, in 2010, human frataxin was shown 
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to accelerate cysteine desulfurase activity, thereby providing an alternate hypothesis to explain the 
observed acceleration in iron sulfur cluster biosynthesis70. Third, it was later revealed that the 
acceleration and inhibition by human and E. coli frataxin respectively actually depend on the type 
of cysteine desulfurase used76. So, when E. coli (prokaryotic) cysteine desulfurase was used both 
frataxin and CyaY would inhibit whereas when human (eukaryotic) cysteine desulfurase was used, 
both of them would activate. This tied up the function of frataxin with cysteine desulfurase activity 
and raised the fundamental question how exactly the function of frataxin is tied with cysteine 
desulfurase mechanism and how the same frataxin activating human cysteine desulfurase whereas 
inhibiting iron sulfur cluster synthesis in E. coli? These questions set up the foundation of this 
Ph.D. work. 
 To address these questions, a thorough investigation was undertaken where we would 
determine the effect of frataxin in each and every step of iron sulfur cluster biosynthesis up to the 
generation of holo-glutaredoxin, which is intermediate cluster carrier for target proteins. For this 
purpose, we divided the whole pathway into four major steps – 1) cysteine desulfurase activity 
(persulfide formation on cysteine desulfurase), 2) sulfur transfer (transfer of sulfane sulfur from 
cysteine desulfurase to scaffold protein generating a persulfide on scaffold protein), 3) cluster 
synthesis (on scaffold protein by combining persulfide, ferrous iron and electron) and 4) cluster 
transfer (from scaffold protein to glutaredoxin). A novel assay (involving use of radioactive 
cysteine as substrate, acid quenching, separation of proteins by HPLC and quantification of 
persulfide) was designed to determine the amounts of persulfide formed on cysteine desulfurase 
and scaffold protein with time. Fit of the data gave us new insight into frataxin function. We found 
in human system, frataxin accelerated both persulfide formation on NFS1 and ISCU2 whereas in 
E. coli system CyaY inhibited persulfide formation on IscU and didn’t affect persulfide formation 
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on IscS. This gave the explanation of frataxin based activation and inhibition. When monitored 
iron sulfur cluster formation on scaffold protein, the effect of activation/inhibition in the upstream 
step(s) were evident. Further analysis into the effect of frataxin in the downstream revealed that 
both frataxin and CyaY had no effect on cluster transfer from scaffold protein to glutaredoxin in 
both E. coli and human system. However, under one-pot experimental setting, cluster formation 
on glutaredoxin was accelerated/inhibited in human/E. coli system respectively as a result of 
upstream activation/inhibition. Further analysis of the upstream steps to understand the molecular 
basis of the effect of frataxin/CyaY on persulfide formation on cysteine desulfurase revealed that 
both frataxin and CyaY accelerates quinonoid decay in human whereas CyaY has no effect in E. 
coli. This raised two important questions -1) what is the source of proton for quinonoid decay? 2) 
how frataxin facilitates proton donation to accelerate quinonoid decay? It has been previously 
hypothesized that the conserved S-transfer loop cysteine may be the proton donor126-127. When this 
residue was mutated to alanine, quinonoid decay was inhibited significantly (almost no decay) in 
both human and E. coli cysteine desulfurase indicating that cysteine residue in indeed the proton 
donor. Interestingly, the cysteine to alanine mutation also caused marked reduction in the 
maximum amount of quinonoid formed. To account for this, we reasoned that S-transfer loop 
cysteine must also be facilitating aldimine formation, which translates into greater quinonoid 
accumulation. Measurement of aldimine and ketimine kinetics of the cysteine to alanine mutants 
revealed this to be true i.e. aldimine formation was significantly reduced and ketimine formation 
was significantly affected as a result of very slow quinonoid decay. This established S-transfer 
loop cysteine as the main player of cysteine desulfurase mechanism where it 1) facilitates aldimine 
formation, 2) supply proton for quinonoid decay, 3) cleave C-S bond to generate persulfide and 4) 
carries the sulfane sulfur to sulfur acceptors. Interestingly all these steps were accelerated by 
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frataxin. Furthermore, all these steps were faster in E. coli IscS than SDAUF. A recent crystal 
structure of human cysteine desulfurase (PDB 5USR) revealed a very different quaternary 
architecture where the cysteine desulfurase subunits are interacting with each other through ISD11 
subunits (instead of directly as in the case of IscS). In this architecture, although a dimer, the active 
site of SDA is solvent exposed (hence we call it open architecture) and very differently than IscS. 
These factors led to the hypothesis that cysteine desulfurase activity depends on the availability of 
the S-transfer loop thiol.  In the case of SDAU, in the open architecture, S-transfer loop is free to 
adopt any number of trajectories resulting in very low probability of adopting the productive loop 
trajectory (which enables S-transfer loop cysteine to perform all four functions). As a result, SDAU 
has very low activity in all steps. In case of IscS, the closed architecture prevents most of the non-
productive loop trajectories, thereby increasing the probability of adopting productive loop 
trajectory. This accelerates all four steps performed by S-transfer loop cysteine and results in high 
activity. We hypothesize that in human frataxin functions as a pseudo subunit of NFS1, binds 
where the other subunit would have bound and increase activity similar to IscS but to a lesser 
extent. This also means that frataxin binding to cysteine desulfurase is fundamentally different, 
which can explain different activation/inhibition properties of FXN/CyaY depending on cysteine 
desulfurase. 
 This then raises some important questions – 1) why human (most likely all eukaryotic) 
cysteine desulfurase has open architecture, 2) if cysteine desulfurase with open architecture indeed 
has low activity (comparable to SDAU), 3) whether frataxin would be able to rescue activity of 
the monomer in case it has low activity, 4) whether the eukaryotic-specific accessory protein 
ISD11 plays any additional role in frataxin based activation and finally 5) how did ancestors cope 
with this transition? Especially, alpha-proteobacteria (which share common ancestors with 
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mitochondria), which is expected to be monomer (hence have open architecture) based on 
sequence and does not contain ISD11. To address these questions, we first decided to find residues 
in the dimer interface which may explain open architecture of NFS1 and when altered, would break 
IscS dimer into the monomer. We found three potential residues, changed them into the 
corresponding residues of NFS1 and found that one mutation (S→Q) indeed caused weaker dimer 
interface, large amounts of the monomer at assay condition and decreased activity which 
corresponds very well with the proportion of dimer. Other double mutation (H→P, Q→L) also 
reduced kcat by half indicating it also may contribute towards dimer stability. Further analysis of 
this double mutant and the triple mutant (S→Q, H→P, Q→L) is underway.  
 Very recently a second crystal structure of human cysteine desulfurase revealed an IscS 
type architecture (closed architecture) complicating our understanding. We then looked into some 
active site residues that may explain the low activity of human cysteine desulfurase. We exchanged 
the residues between IscS and NFS1 and none of the variants in IscS showed activity similar to 
SDA. This strongly suggests this architecture may an artifact of crystallization and may not be 
physiologically relevant. 
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